

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 03/104437 A2

- (51) International Patent Classification⁷: C12N Avenue, Los Angeles, CA 90069 (US). **ROZOFSKY, Irina** [US/US]; 2437 San Pasqual, Pasadena, CA 91107 (US). **FINCH, Caleb, E.** [US/US]; 2144 Crescent Drive, Altadena, CA 91101 (US).
- (21) International Application Number: PCT/US03/19640
- (22) International Filing Date: 11 June 2003 (11.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
10/166,856 11 June 2002 (11.06.2002) US
- (71) Applicants (for all designated States except US): **NORTHWESTERN UNIVERSITY** [US/US]; 633 North Clark Street, Evanston, IL 60208 (US). **UNIVERSITY OF SOUTHERN CALIFORNIA** [US/US]; University Park Campus, Los Angeles, CA 90089 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KLEIN, William, L.** [US/US]; 1145 Chatfield Road, Winnetka, IL 60093 (US). **KRAFFT, Grant, A.** [US/US]; 1309 Evergreen Court, Glenview, IL 60025 (US). **LAMBERT, Mary, P.** [US/US]; 1956 Linneman Street, Glenview, IL 60025 (US). **VIOLA, Kirsten, L.** [US/US]; 850 North Dewitt Place, Unit 6K, Chicago, IL 60611 (US). **CHROMY, Brett, A.** [US/US]; 3653 Pimlico Drive, Pleasanton, CA 94588 (US). **GONG, Yue, Song** [CN/US]; 825 Foster Street, Apt. 301, Evanston, IL 60201 (US). **CHANG, Lei** [CN/US]; 1915 Maple Street, Apt. 924, Evanston, IL 60201 (US). **MORGAN, Todd, E.** [US/US]; 1681 Marmot
- (74) Agent: **CHAEEL, Mark, L.**; McDonnell Boehnen Hulbert & Berghoff, 32nd Floor, 300 South Wacker Drive, Chicago, IL 60606 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/104437 A2

(54) Title: ANTI-ADDL ANTIBODIES AND USES THEREOF

(57) Abstract: The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, *inter alia* in the treatment of learning and/or memory disorders.

This application is related to U.S. Patent App. No. 60/086,582, filed May 22, 1998; International Patent App. No. PCT/US98/02426, filed February 5, 1998, which was published as WO 98/33815 on August 6, 1998; and International
5 Patent App. No. PCT/US00/21458, filed Aug. 4, 2000, which was published as WO 01/10900 on February 15, 2001.

Alzheimer's disease (AD) is the most common cause of dementia in older individuals. No effective treatment exists, however significant research progress has led to a general consensus that elevated levels of $A\beta_{1-42}$, the longer form of
10 the amyloid beta peptide, are responsible for the disease. Exactly how such elevated levels of $A\beta_{1-42}$ lead to the disease has not been precisely elucidated, but the most frequently invoked and longstanding explanation is the amyloid cascade hypothesis involving deposition of amyloid fibrils and the purported toxic activity thereof (Hardy, J.A. & Higgins, G.A. (1992) *Science*, vol. 256, pp. 184-
15 185; Small, D.H. (1998) *Amyloid*, vol. 5, pp. 301-304; Golde, T.E. (2000) *Biochim. Biophys. Acta*, vol. 1502, pp. 172-187). Other published studies claim that multiple factors are involved, including CNS inflammation, oxidative damage, and cytoskeletal anomalies (McGeer, P.L. & McGeer, E.G. (1999) *J. Leukoc. Biol.*,
vol. 65, pp. 409-415; Mandelkow, E.M. & Mandelkow, E. (1998) *Trends Cell Biol.*,
20 vol. 8, pp. 425-427; Spillantini, M.G. & Goedert, M. (1998) *Trends Neurosci.*, vol. 21, pp. 428-433; Smith, M.A. *et al.* (1995) *Trends Neurosci.*, vol. 18, pp. 172-176), but these phenomena have been argued to be caused by elevated $A\beta_{1-42}$ levels, and not themselves the root cause of the disease.

$A\beta_{1-42}$ is a 42-amino acid amphipathic peptide derived proteolytically from
25 a widely expressed membrane precursor protein (Selkoe, D.J. (1994) *Annu. Rev. Neurosci.*, vol. 17, pp. 489-517). As a monomer, the amyloid peptide has never been demonstrated to have toxic effects, and in some studies it has been purported to have neurotrophic effects.

Monomers of $A\beta_{1-42}$ assemble into at least three neurotoxic species:
30 fibrillar amyloid (Pike, C.J. *et al.* (1993) *J. Neurosci.*, vol. 13, pp. 1676-1687; Lorenzo, A. & Yanker, B.A. (1994) *Proc. Natl. Acad. Sci. USA*, vol. 91, pp. 12243-12247), protofibrils (Hartley, D.M. *et al.* (1999) *J. Neurosci.*, vol. 19, pp. 8876-8884; Walsh, D.M. *et al.* (1999) *J. Biol. Chem.*, vol. 274, pp. 25945-25952, and

A β ₁₋₄₂-derived diffusible ligands (ADDLs) (Lambert, M.P. *et al.* (1998) *Proc. Natl. Acad. Sci. USA*, vol. 95, pp. 6448-6453). Fibrillar amyloid is insoluble, and deposits of fibrillar amyloid are easily detected in AD and transgenic mice because of their birefringence with dyes such as thioflavin S. Fibrillar amyloid is a major protein component of senile plaques in Alzheimer's disease brain. A β peptides of various lengths, including A β 1-40, 1-42, 1-43, 25-35, and 1-28 assemble into fibrils *in vitro*. All of these fibrils have been reported to be toxic to neurons *in vitro* and to activate a broad range of cellular processes. Hundreds of studies describe A β fibril neurotoxicity, but numerous studies also describe poor reproducibility and highly variable toxicity results. The variability has been attributed, in part, to batch-to-batch differences in the starting solid peptide and these differences relate specifically to the various physical or aggregation states of the peptide, rather than the chemical structure or composition. Protofibrils are large yet soluble meta-stable structures first identified as intermediates en route to full-sized amyloid fibrils (Walsh, D.M. *et al.* (1997) *J. Biol. Chem.*, vol. 272, pp. 22364-22372).

ADDLs comprise small soluble A β ₁₋₄₂ oligomers, predominantly trimers and tetramers but also higher-order species (Lambert, M.P. *et al.* (1998) *Proc. Natl. Acad. Sci. USA*, vol. 95, pp. 6448-6453; Chromy, B.A. *et al.* (2000) *Soc. Neurosci. Abstr.*, vol. 26, p. 1284). All three forms of assembled A β ₁₋₄₂ rapidly impair reduction of the dye MTT (Shearman, M.S. *et al.* (1994) *Proc. Natl. Acad. Sci. USA*, vol. 91, pp. 1470-1474; Walsh, D.M. *et al.* (1999) *J. Bio. Chem.*, vol. 274, pp. 25945-25952; Oda, T. *et al.* (1995) *Exp. Neurol.*, vol. 136, pp. 22-31), possibly the consequence of impaired vesicle trafficking (Liu, Y. & Schubert, D. (1997) *J. Neurochem.*, vol. 69, pp. 2285-2293), and they ultimately kill neurons (Longo, V.D. *et al.* (2000) *J. Neurochem.*, vol. 75, pp. 1977-1985; Loo, D.T. *et al.* (1993) *Proc. Natl. Acad. Sci. USA*, vol. 90, pp. 7951-7955; Hartley, D.M. *et al.* (1999) *J. Neurosci.*, vol. 19, pp. 8876-8884). All three forms also exhibit very fast electrophysiological effects. Amyloid and protofibrils broadly disrupt neuronal membrane properties, inducing membrane depolarization, action potentials, and increased EPSPs (Hartley, D.M. *et al.* (1999) *J. Neurosci.*, vol. 19, pp. 8876-8884), while ADDLs selectively block long-term potentiation (LTP) (Lambert, M.P. *et al.* (1998) *Proc. Natl. Acad. Sci. USA*, vol. 95, pp. 6448-6453; Wang, H. *et al.*

(2000) *Soc. Neurosci. Abstr.*, vol. 26, pp. 1787; Wang et al. (2002), *Brain Research* 924, 133–140). ADDLs also show selectivity in neurotoxicity, killing hippocampal but not cerebellar neurons in brain slice cultures (Kim, H.-J. (2000) Doctoral Thesis, Northwestern University, pp. 1-169). Given the poor correlation
5 between fibrillar amyloid and disease progression (Terry, R.D. (1999) in *Alzheimer's Disease* (Terry, R.D. et al., Eds.), pp. 187-206, Lippincott Williams & Wilkins), it is likely that fibrillar amyloid deposits are not the toxic form of A β ₁₋₄₂ most relevant to AD. Non-fibrillar assemblies of A β occur in AD brains (Kuo, Y.M. et al. (1996) *J. Biol. Chem.*, vol. 271, pp. 4077-4081; Roher, A.E. et al. (1996) *J.*
10 *Biol. Chem.*, vol. 271, pp. 20631-20635; Enya, M. et al. (1999) *Am. J. Pathol.*, vol. 154, pp. 271-279; Funato, H. et al. (1999) *Am. J. Pathol.*, vol. 155, pp. 23-28; Pitschke, M. et al. (1998) *Nature Med.*, vol. 4, pp. 832-834) and these species appear to correlate better than amyloid with the severity of AD (McLean, C.A. et al. (1999) *Ann. Neurol.*, vol. 46, pp. 860-866; Lue, L.F. et al. (1999) *Am. J.*
15 *Pathol.*, vol. 155, pp. 853-862). Soluble A β oligomers are likely to be responsible for neurological deficits seen in multiple strains of transgenic mice that do not produce amyloid plaques (Mucke, L. et al. (2000) *J. Neurosci.*, vol. 20, pp. 4050-4058; Hsia, A.Y. et al. (1999) *Proc. Natl. Acad. Sci. USA*, vol. 96, pp. 3228-3233; Klein, W.L. (2000) in *Molecular Mechanisms of Neurodegenerative Diseases*
20 (Chesselet, M.-F., Ed.), Humana Press; Klein, W.L. et al. (2001) *Trends Neurosci.*, vol. 24, pp. 219-224).

Over the past 3 years, a novel therapeutic strategy for Alzheimer's disease has emerged, based on vaccination with aggregated A β preparations. The initial studies that utilized this approach involved transgenic AD model mice that were
25 vaccinated with A β fibrils, a procedure which was reported to afford some protection from behavioral deficits normally manifest in these mice (Schenk, D. (1999) *Nature*, vol. 400, pp. 173-177; Morgan D.G. et al. (2001) *Nature*, in press; Helmuth, L. (2000) *Science*, vol. 289, p. 375; Arendash, G. et al. (2000) *Soc. Neurosci. Abstr.*, vol. 26, p. 1059; Yu, W. et al. (2000) *Soc. Neurosci. Abstr.*, vol.
30 26, p. 497). This result was surprising because it had generally not been appreciated that effective immune protection could be conferred on the brain side of the blood brain barrier (BBB). Apparently the protective effects observed in these transgenic AD mouse vaccination studies resulted from direct transport of

anti-amyloid antibodies across the blood brain barrier in sufficient quantities to reduce the levels of toxic amyloid structures. Alternatively, it is conceivable that antibodies circulating in the bloodstream were capable of binding and clearing amyloid in sufficient quantities to reduce brain levels and produce a beneficial symptomatic effect. Several of the Tg mouse vaccination studies reported that total brain amyloid levels had not been lowered significantly, compared with amyloid levels in unvaccinated Tg AD mice in the control groups, which raises doubts about the plausibility of the A β clearance mechanism.

In other studies, it was demonstrated that direct injection of anti-amyloid antibodies into the brains of transgenic AD mice resulted in a significant reduction in brain amyloid levels (Bard, F. *et al.* (2000) *Nature Med.*, vol. 6, pp. 916-919), however this approach involved delivery of antibody levels significantly higher than could be expected from passive transport across the BBB.

Regardless of the operative mechanism in these vaccinated Tg AD mice, the promising behavior protection results provided ample impetus to move forward with human testing of a fibrillar Ab vaccine AN1792 by the Elan Corporation (Helmuth, L. (2000) *Science*, vol. 289, p. 375). Their successful Phase I safety studies led to initiation of Phase II efficacy studies in AD patients. Unfortunately, these Phase II studies were halted recently because 12 of 97 AD patients in the study had developed vaccine related complications involving brain inflammation and encephalitis. Although the specific reason(s) for these serious complications is not known definitively, it can be surmised that vaccination with Ab fibrils would generate a significant immune response to the amyloid plaques in the brain, and that this would result in persistent activation of microglial cells and production of inflammatory mediators, all of which would contribute to severe encephalitis. In fact, this glial activation mechanism is precisely the mechanism proposed to explain the efficacy of the Elan vaccine approach (Schenk, D. (1999) *Nature*, vol. 400, pp. 173-177).

These sobering results now make it very clear that any successful immune strategy for prevention or therapy of AD, whether involving a vaccine or a therapeutic antibody, will require a much more selective approach that targets toxic structures directly and specifically.

The present invention provides just such an approach that is independent of amyloid clearance, whether fibrillar or monomeric. The present invention provides an immune strategy that directly targets and neutralizes ADDLs. In the present invention, antibodies that have been generated and selected for the ability to bind ADDLs specifically, without binding to A β monomer or amyloid fibrils, will be employed to treat and prevent disease that results from the action of ADDLs in the brain. The present invention further uses such antibodies for specific diagnosis of individuals who have measurable levels of ADDLs present in the brain or CSF. Additionally, the present invention uses anti-ADDL antibodies in assays that allow for the detection of molecules that block the formation or activity of ADDLs.

Previous immunization protocols such as that used by Elan Corporation, have used aggregated solutions of A β ₁₋₄₂ that contain multiple forms of A β ₁₋₄₂ in undefined proportions. The invention described herein is based on the use of well-defined ADDL preparations consisting of A β ₁₋₄₂ monomers and small oligomers, injected at low doses. The data presented herein show that A β ₁₋₄₂ oligomers are more potent immunogens than A β monomer, giving rise to antibodies that preferentially recognize ADDLs in immunoblots, detect puncta of ADDLs bound to cell surfaces in immunohistochemistry protocols, and block the toxic action of ADDLs on cultured PC12 cells. These results strongly support the hypothesis that therapeutic antibodies targeting small non-fibrillar A β ₁₋₄₂ toxins would be effective agents to stop and prevent AD pathogenesis.

BRIEF SUMMARY OF THE INVENTION

The present invention seeks to overcome the substantial problems with the prior art that are based largely on the flawed theory that amyloid fibrils and plaques cause AD. Accordingly, one object of the present invention is the production, characterization and use of new compositions comprising specific ADDL-binding molecules such as anti-ADDL antibodies, which are capable of direct or indirect interference with the activity and/or formation of ADDLs (soluble, globular, non-fibrillar oligomeric A β ₁₋₄₂ assemblies). These and other objects and

advantages of the present invention, as well as additional inventive features, will be apparent from the description herein.

The present invention pertains to amyloid beta-derived diffusible ligands (ADDLs), antibodies that bind to ADDLs (anti-ADDL antibodies), uses of anti-ADDL antibodies to discover anti-ADDL therapeutics, and uses of anti-ADDL antibodies in the diagnosis, treatment and prevention of diseases associated with ADDLs, including Alzheimer's disease, learning and memory disorders, and neurodegenerative disorders. The invention specifically pertains to antibodies that recognize and bind ADDLs preferentially, with much lower binding capability for monomer forms of the amyloid peptide. Antibodies with these characteristics are useful for blocking the neurotoxic activity of ADDLs, and they are useful for eliminating ADDLs from the brain via clearance of antibody-ADDL complexes. Antibodies with these characteristics also are useful for detection of ADDLs in biological samples, including human plasma, cerebrospinal fluid, and brain tissue. Anti-ADDL antibodies are useful for quantitative measurement of ADDLs in cerebrospinal fluid, enabling the diagnosis of individuals adversely affected by ADDLs. Such adverse effects may manifest as deficits in learning and memory, alterations in personality, and decline in other cognitive functions such as those functions known to be compromised in Alzheimer's disease and related disorders. Anti-ADDL antibodies are also useful for quantitative detection of ADDLs in brain tissue obtained at autopsy, to confirm pre-mortem diagnosis of Alzheimer's disease.

The invention further pertains to antibodies that recognize and bind ADDLs preferentially, with much lower binding capability for fibrillar and monomer forms of the amyloid peptide. Such antibodies are particularly useful for treatment and prevention of Alzheimer's disease and other ADDL-related diseases in patients where prevalent fibrillar amyloid deposits exist in the brain, and for whom treatment with antibodies that preferentially bind to fibrillar forms of amyloid will result in serious brain inflammation and encephalitis.

The invention further pertains to the use of ADDLs to select or identify antibodies or any other ADDL binding molecule or macromolecule capable of binding to ADDLs, clearing ADDLs from the brain, blocking ADDL activities, or preventing the formation of ADDLs. Additional inventions include new composition of matter, such molecule being capable of selecting antibodies or

anti-ADDL binding molecules, or inducing an ADDL blocking immune response when administered to an animal or human. The invention extends further to include such uses when applied to methods for creating synthetic antibodies and binding molecules and other specific binding molecules through selection or recombinant engineering methods as are known in the art.

Specifically, the invention pertains to the preparation, characterization and methods of using such anti-ADDL antibodies. The invention also pertains to the use of anti-ADDL antibodies for the detection of ADDL formation and for the detection of molecules that prevent ADDL formation. The invention further pertains to the use of such antibodies to detect molecules that block ADDL binding to specific ADDL receptors present on the surface of nerve cells that are compromised in Alzheimer's disease and related disorders.

ADDLs comprise amyloid β ($A\beta$) peptide assembled into soluble, globular, non-fibrillar, oligomeric structures that are capable of activating specific cellular processes. Disclosed herein are methods for preparing and characterizing antibodies specific for ADDLs as well as methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. Also described are compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. ADDL formation and activity are relevant *inter alia* to compromised learning and memory, nerve cell degeneration, and the initiation and progression of Alzheimer's disease. Modulation of ADDL formation or activity thus can be employed according to the invention in the treatment of learning and memory disorders, as well as other diseases, disorders or conditions that are due to the effects of the ADDLs.

The invention pertains to new compositions of matter, termed amyloid beta-derived diffusible ligands or amyloid beta-derived dementing ligands (ADDLs). ADDLs consist of amyloid β peptide assembled into soluble non-fibrillar oligomeric structures that are capable of activating specific cellular processes. A preferred aspect of the present invention comprises antibodies and binding molecules that are specific for ADDLs, and methods for preparation, characterization and use of antibodies or binding molecules that are specific for ADDLs. Another preferred embodiment comprises antibodies or binding molecules that bind to ADDLs but do not bind to $A\beta$ monomers or fibrillar

aggregates. Another aspect of the invention consists of methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs, and methods for diagnosing diseases or potential diseases resulting from the presence of ADDLs. A further aspect of the invention is the use of anti-ADDL
5 antibody or anti-ADDL binding molecules for the therapy and/or prevention of Alzheimer's disease and other diseases associated with the presence of ADDLs. The invention further encompasses assay methods and methods of identifying compounds that modulate (e.g., increase or decrease) the formation and/or activity of ADDLs. Such compounds can be employed in the treatment of
10 diseases, disorders, or conditions due to the effects of the ADDLs.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Figure 1 is a computer-generated image of a densitometer-scanned silver-stained polyacrylamide gel which shows the ADDLs electrophoresing with a
15 primary band corresponding to about 30 kD, a less abundant band corresponding to about 17 kD, and no evidence of fibrils or aggregates.

Figure 2 is a computer-generated image of a densitometer-scanned Coomassie-stained SDS-polyacrylamide gel which shows ADDLs
20 electrophoresing with a primary band (upper doublet) corresponding to a size of about 17 to about 22 kD, and with another band (lower dark band) indicating abundant 4 kD monomer present, presumably a breakdown product. *Lanes*: first, molecular size markers; second ADDL preparation; third, heavier loading of ADDL preparation.

Figure 3 is a representative computer-generated image of AFM analysis of
25 ADDL-containing "fraction 3" (fractionated on a Superdex 75 gel filtration column).

Figure 4 is a computer-generated image of a densitometer-scanned Coomassie-stained SDS-polyacrylamide gradient gel of ADDLs prepared by
30 coincubation with clusterin (*lane A*) or cold F12 media (*lane B*), and of ADDLs prepared by coincubation with clusterin and which passed through a Centricon 10 kD cut-off membrane (*lane C*) or were retained by a Centricon 10 kD cut-off membrane (*lane D*). MW, molecular size markers.

Figure 5 is a graph of ADDL concentration measured as amyloid β 1-42 concentration (nM) vs. % dead cells for brain slices from mice treated with the ADDL preparations.

5 Figure 6 is a bar chart showing % MTT reduction for control PC 12 cells not exposed to ADDLs ("Cont."), PC 12 cells exposed to clusterin alone ("Apo J"), PC 12 cells exposed to monomeric A β ("A β "), PC12 cells exposed to amyloid β coaggregated with clusterin and aged one day ("A β :Apo J").

10 Figure 7 is a FACScan showing fluorescence intensity (0-170) versus events (0-300) for B103 cells not exposed to ADDLs (unshaded peak) and B103 cells bound to fluorescent labeled ADDLs (shaded peak).

Figure 8 is a FACScan showing fluorescence intensity (0-200) versus events (0-300) for hippocampal cells not exposed to ADDLs (unshaded peak, "-ADDLs") and hippocampal cells bound to fluorescent labeled ADDLs (shaded peak, "+ADDLs").

15 Figure 9 is a bar chart of percent maximum ADDL binding or ADDL-evoked death for B103 cells that either have been not exposed ("-") or coexposed ("+") to the peptides released by trypsinization of B103 cells.

20 Figure 10 is a graph of relative ADDL concentration vs. % dead cells for brain slices from mice treated with the ADDL preparations. To determine relative concentration, an initial concentration of 10 μ M A β protein was employed to form ADDLs at the highest data point (point "16"), this was subsequently diluted to $\frac{1}{2}$ (point "8"), $\frac{1}{4}$ (point "4"), and the like.

25 Figure 11 is a bar chart showing optical density obtained in the ADDL binding ELISA assay wherein B103 cells were coincubated with ADDLs and 6E10 antibody ("cells, ADDL, 6E10" bar), B103 cells were coincubated with ADDLs ("cells, ADDL" bar), B103 cells were coincubated with 6E10 antibody ("cells, 6E10" bar), B103 cells were incubated alone ("cells" bar), 6E10 antibody was incubated alone ("6E10" bar), or the optical density of diluent was read ("blank" bar).

30 Figure 12 is a bar chart of % dead cells in either *fyn* +/+ (wild type, "Fyn +"; crosshatched bars) or *fyn* -/- (knockout, "Fyn -"; solid bars) mice either not treated ("Medium") or contacted with ADDLs ("ADDLs").

Figure 13 is a graph of A β concentration (μ M) versus activated glia (number) obtained upon incubation of astrocytes with ADDLs (filled triangles) or A β 17-42 (filled squares).

Figure 14 is a graph of time (minutes) versus % baseline cell body spike amplitude for control mice not treated with ADDLs (filled triangles) or mice treated with ADDLs (filled squares).

Figure 15 is a graph of time (minutes) versus mean spike amplitude for control rat hippocampal slices not exposed to ADDLs (filled triangles) versus rat hippocampal slices exposed to ADDLs (filled squares).

Figure 16 is a computer-generated image of a densitometer-scanned 16.5% tris-tricine SDS-polyacrylamide gel (Biorad) which shows a range of oligomeric, soluble ADDLs (labeled "ADDLs"), and amyloid β dimer (labeled "Dimer"), and monomer (labeled "Monomer"). *Lanes:* first, silver stained Mark XII molecular weight standards (Novex, San Diego, California); second, silver stained ADDLs; third, Western blot of second lane using the monoclonal antibody 26D6 (Sibia Neurosciences, San Diego, California).

Figure 17 is a computer-generated image of an AFM analysis of ADDLs. The top view subtracted image shows a high magnification view (2.0 μ m x 2.0 μ m) of aggregated amyloid β molecules that have been spotted on freshly cleaved mica.

Figure 18 displays data showing that ADDLs maintain their oligomeric profile and cytotoxic activity after storage at 4°C. *A. Silver stain of initial ADDL preparation and the same preparation one day later.* A β ₁₋₄₂ was dissolved in DMSO, then in F12 (see Example 22, Materials and Methods), and incubated at 4°C for 24 hours. After centrifugation, the supernatant, which represents the initial ADDL preparation, was removed to a new tube. Supernatant proteins were separated on a Tris tricine gel using SDS-PAGE and visualized with a silver stain. Lane 1: Colored molecular weight markers (not silver stained). Lane 2: Initial ADDL preparation showing abundant monomer, slight dimer, and substantial trimer and tetramer oligomers. Lane 3: ADDL preparation one day later at 4°C showing essentially the same profile. In this image, the uniform gray background of these two lanes is from the colored background of the silver stain. *B. MTT Assay of initial ADDL preparation and the same preparation one day later.* The

MTT assay was used to compare the effect of a 4-hour ADDL incubation on PC12 cells (Example 22, Materials and Methods). Whether fresh or stored, ADDL preparations caused at least 50% inhibition. Data from A and B indicate that the 48-hour sample, which was used for injection, is similar in structure and toxicity to the initial preparation.

Figure 19 presents data showing that antibody M94 displays a strong preference for oligomers in immunoblots. ADDLs were separated using SDS-PAGE, transferred to nitrocellulose, and probed with the indicated antibodies. Binding was identified with a secondary conjugated to horseradish peroxidase and visualized using chemiluminescence. The monoclonal antibody 4G8 (right lane) recognizes four A β species, from monomer to tetramer. The monoclonals 26D6 (middle lane) and 6E10 (Fig. 3) recognize monomer, trimer, and tetramer, but not dimer. The new polyclonal antisera M94 (left lane) and M93 (Fig. 3) preferentially recognize oligomers.

Figure 20 presents data showing that the oligomer-selective M93 antibody detects amyloid β monomer only at high antibody concentrations. *A. Immunoblot:* An ADDL immunoblot was probed with decreasing concentrations of antibody. Visualization of ADDLs was by chemiluminescence. M93 potency is at least that of 6E10, a commercial monoclonal antibody unselective for oligomers that is shown for reference (at a dilution of 1:2000). *B. Quantification of chemiluminescent bands:* The intensity of each band was determined by image analysis (Methods) and normalized to the 6E10 monomer band (100%). M93 antibody bound monomer only at higher antibody concentrations (<1:500 dilution). These data indicate that oligomers are preferentially recognized by M93 antibody.

Figure 21 presents data showing that pre-absorption of oligomer-selective antibodies with ADDLs eliminates binding in immunoblots. Each antibody (as indicated) was incubated with ADDLs for 2 hours at 0, 1, 5, or 10 times the protein concentration. Then the solutions were used on an ADDL immunoblot that was developed in the standard manner. Prior absorption by ADDLs eliminates all binding. This result indicates that binding of the antibodies to ADDLs requires specific recognition.

Figure 22 presents data showing that oligomer-selective antibodies exhibit no binding to normal brain proteins. In order to determine if the antibodies bind to brain proteins other than ADDLs, rat brain homogenate was prepared and separated alone or in the presence of ADDLs using SDS-PAGE. ADDLs were added to protein (60 μ g) immediately before electrophoresis. The resulting immunoblot was probed with M94 and binding visualized with chemiluminescence. No binding occurred to brain proteins alone (middle lane). Samples that had ADDLs and homogenate (right lane) showed tetramer and trimer (closed arrow) as well as higher molecular weight species. The most prominent of these bands are indicated by the open arrow, with trace amounts showing up at higher molecular weights. ADDLs alone are shown in the left lane. These results indicate that the antibodies recognize only A β oligomers and not brain proteins.

Figure 23 presents data showing the localization of ADDL binding in cultured rat hippocampal cells. Rat hippocampal cultures were prepared, exposed to ADDLs for 90 min., and then fixed. Bound ADDLs were identified using M94 antibody and visualized with secondary IgG conjugated to Oregon green-514. The top panels are immunofluorescence images; the bottom panels are inverted fluorescent images. Left: cultures were treated with ADDLs but no primary antibody. Middle: cultures were treated with ADDLs and M94 antibody. Right: cultures were treated with vehicle control and M94 antibody. There is no binding to primary- or ADDL-free cultures. Label seen in cultures treated with both ADDLs and M94 is located almost exclusively on neurites. The bar in the lower left corner represents 25 microns.

Figure 24 presents data showing that toxicity to PC12 cells (as measured by an MTT assay) is blocked by ADDL-selective antibodies. Pre-immune serum was added to ADDLs for 2 hours before the MTT reaction was performed in PC12 cells. This addition does not prevent the reduction of MTT in a dose-dependent manner (open squares, bottom line). However, if antibodies are pre-incubated with ADDLs for 2 hours, no change in MTT reduction is seen (filled squares, top line). These data indicate that the antibodies block the action of ADDLs.

DETAILED DESCRIPTION OF THE INVENTION

A β -derived oligomers (ADDLs) are effective antigens, eliciting antibodies that are analytically useful and potentially of therapeutic and prophylactic value. The antibodies discriminate oligomers from monomers, and they exhibit efficacy and specificity in immunoblots and immunofluorescence microscopy. The antibodies, moreover, neutralize the biological activity of ADDLs. This is significant because emerging evidence suggests that ADDLs are the relevant pathogenic molecules that form when levels of A β ₁₋₄₂ become elevated. Unlike deposited amyloid, ADDLs are small neurotoxins that are soluble and diffusible. They have been demonstrated to interfere directly with the key electrophysiology and biochemistry required for information storage, namely LTP. Therefore, the ability to neutralize these soluble toxins may be highly significant for therapeutic intervention in Alzheimer's disease and related disorders.

The antibodies induced by ADDL preparations show specificity for oligomers. In some instances, monomers can be detected at very high doses of antibodies, but serial dilutions establish that antibodies from several animals (designated 90, 93 or 94) preferentially recognize and bind to oligomers (Fig. 19 and Fig. 20). It should be noted these ADDL preparations do not convert to protofibrils or fibrils, eliminating the possibility that these larger assemblies could be responsible for generating the observed immune response.

Several possibilities could cause oligomers to be more antigenic than monomer. One possibility might be that the oligomers may be inherently more immunogenic due to presentation of novel, conformationally dependent epitopes, absent from monomer. Monomers also are likely to be intrinsically less immunogenic because of their physiological role consequent to normal metabolism of APP molecules (Selkoe, D.J. (1994) *Annu. Rev. of Neurosci.*, vol. 17, pp. 489-517), which are transiently abundant during development (Enam, S.A. (1991) Ph.D. Thesis, Northwestern University). Another possibility might be that monomers may be cleared more efficiently than oligomers.

The binding affinities and detection efficacies of ADDL-antibodies are comparable to commercial A β monoclonal antibodies (Fig. 19). For example, at higher ADDL concentrations (100 pmol), ADDL-antibodies at 0.3 μ g/ml show a

binding intensity comparable to that of commercial monoclonal antibodies used at 0.4 to 0.5 $\mu\text{g/ml}$ (Fig. 19). These commercial monoclonals also recognized epitopes common to several states of $\text{A}\beta$ assembly, including monomers and dimers, which were not detected by anti-ADDL antibodies. That alternative
5 assembly-states of $\text{A}\beta$ manifest different epitopes is in harmony with their differing toxic activities, a property that may be exploited for future drug development. ADDL-antibodies also show efficacies that are as least as good as monoclonal antibodies when used at very low $\text{A}\beta$ concentrations (Ida, N. *et al.* (1996) *J. Biol. Chem.*, vol. 271, pp. 22908-22914; Potempska, A. *et al.* (1999)
10 *Amyloid*, vol. 6, pp. 14-21). Immunoblots with ADDL-antibodies at a final IgG protein concentration of 0.6 $\mu\text{g/ml}$ can recognize less than 1 fmol of ADDLs.

Besides potency, the antibodies show significant specificity, making them useful for analytical experiments. This is not always the case for other antibodies produced against $\text{A}\beta$ peptides. For example, some monoclonal antibodies
15 against $\text{A}\beta_{35-42}$ and $\text{A}\beta_{33-40}$ bind non-specifically to components in CSF and blood plasma on immunoblots, even though they are selective for $\text{A}\beta$ in an ELISA (Ida, N. *et al.* (1996) *J. Biol. Chem.*, vol. 271, pp. 22908-22914). The M93 and M94 antibodies (see below) showed no binding to proteins in total rat homogenate, in harmony with their selectivity for oligomer over monomer. Similarly, in
20 immunofluorescence microscopy experiments, the antibodies showed little binding to cell surfaces in the absence of exogenous ADDLs.

Two interesting observations emerge from the immunoblot and immunofluorescence experiments. First, when ADDLs were mixed with brain homogenates, immunoblots showed ADDLs at their normal molecular weight
25 range, but, in addition, species at a higher molecular weight were also observed. The basis for this addition is not known, but it previously has been established that several different proteins can influence the aggregation properties of $\text{A}\beta$ (Klein, W.L. (2000) in *Molecular Mechanisms of Neurodegenerative Diseases* (Chesselet, M.-F., Ed.), Humana Press; Klein, W.L. *et al.* (2001) *Trends
30 Neurosci.*, vol. 24, pp. 219-224). The size of the species seen here ($\sim 30\text{-}40$ kDa) is the same as the size suggested to be a predominant form in AD-afflicted brain (Guerette, P.A. *et al.* (2000) *Soc. Neurosci. Abstr.*, vol. 25, p. 2129). However, the additional species may also be tightly-adherent ADDLs bound to a small brain

protein, e.g., ApoE. A stable complex between A β and ApoE has been seen previously (LaDu, M.J. *et al.* (1997) *J. Neurosci. Res.*, vol. 49, pp. 9-18; LaDu, M.J. *et al.* (1995) *J. Biol. Chem.*, vol. 270, pp. 9039-9042). Second, from neuron culture experiments, immunofluorescence data showed ADDLs became associated with neurons in a highly patterned manner. The nature of these "hot spots" suggests possible receptor involvement in ADDL toxicity (Viola, Gong, Lambert, Lin, and Klein, in preparation).

Somewhat surprising and potentially most significant is the neuroprotection afforded by antibodies at substoichiometric doses. Tests of protection used the MTT reduction assay with PC12 neuron-like cells. In this bioassay, which monitors exocytosis/endocytosis as well as oxidative metabolism (Liu, Y. & Schubert, D. (1997) *J. Neurochem.*, vol. 69, pp. 2285-2293), ADDLs maximally block MTT reduction at doses of 1-5 μ M. Substoichiometric levels of antibodies blocked the ADDL impact, with blockade evident at antibodies/ADDL molar ratios as low as to 1:15. This efficacy is similar to data reporting that guinea pig antibodies can prevent toxicity of amyloid in a PC12 MTT assay at a ratio of 1:20 (Frenkel, D. *et al.* (2000) *Proc. Natl. Acad. Sci. USA*, vol. 97, pp. 11455-11459). In the present case, low relative doses of antibodies appear protective because of their selectivity for toxic oligomers (Figs. 19 and 20). Monomer is not toxic (Yanker, B.A. (1996) *Neuron*, vol. 16, pp. 921-932; Yanker, B.A. *et al.* (1989) *Science*, vol. 245, pp. 417-420), but makes up 45 +/- 5% of the total soluble A β (Chromy, B.C. *et al.*, in preparation). The antibodies thus appear to target and lower the availability of toxic subspecies in the ADDL solution.

Antibodies that target toxic forms of self-assembled A β have become of great interest because of the remarkable recent findings that antibodies against A β cross the blood brain barrier and are therapeutic in transgenic mice models of AD (Bard, F. *et al.* (2000) *Nature Med.*, vol. 6, pp. 916-919; Schenk, D. (1999) *Nature*, vol. 400, pp. 173-177). The vaccination protocols lead to loss of amyloid (Bard, F. *et al.* (2000) *Nature Med.*, vol. 6, pp. 916-919; Schenk, D. (1999) *Nature*, vol. 400, pp. 173-177) and are effective in preventing behavior decline (Helmuth, L. (2000) *Science*, vol. 289, p. 375; Arendash, G. *et al.* (2000) *Soc. Neurosci. Abstr.*, vol. 26, p. 1059; Yu, W. *et al.* (2000) *Soc. Neurosci. Abstr.*, vol.

26, p. 497). The authors of these immunization/vaccination studies have suggested that therapeutic efficacy may be due indirectly to activated microglia, which remove amyloid plaque proteins. Other studies, however, have shown that antibodies made in bacteria and mammals by phage display can directly bring about dissociation of aggregated A β *in vitro* (Frenkel, D. *et al.* (2000) *Proc. Natl. Acad. Sci. USA*, vol. 97, 11455-11459; Frenkel, D. *et al.* (2000) *J. Neuroimmunol.*, vol. 106, pp. 23-31). These antibodies are produced against the EFRH epitope, amino acids #3-6 of A β . This site is hypothesized to be the regulatory site on N-terminals of fibrils (Frenkel, D. *et al.* (1998) *J. Neuroimmunol.*, vol. 88, pp. 85-90).

An alternative explanation for the behavioral efficacy of these antibodies is that they may neutralize soluble ADDLs, which putatively play a pathogenic role in transgenic mice AD models and in AD itself. Multiple transgenic APP mice models show behavioral and degenerative losses in the complete absence of amyloid deposits (Klein, W.L. (2000) in *Molecular Mechanisms of Neurodegenerative Diseases* (Chesselet, M.-F., Ed.), Humana Press; Klein, W.L. *et al.* (2001) *Trends Neurosci.*, vol. 24, pp. 219-224). Recently, *e.g.*, amyloid-free APP-transgenic mice were found to exhibit loss of synaptophysin-immunoreactive terminals, a good measure of cognitive decline in AD (Terry, R.D. (1999) in *Alzheimer's Disease* (Terry, R.D. *et al.*, Eds.), pp. 187-206, Lippincott Williams & Wilkins), in a manner that correlates nonetheless with levels of soluble A β ₁₋₄₂ species (Mucke, L. *et al.* (2000) *J. Neurosci.*, vol. 20, pp. 4050-4058). The authors suggest their results support an emerging view that plaque-independent A β toxicity is important in the development of synaptic deficits in AD. Analogous correlation between synapse loss and soluble A β has been observed in AD (Lue, L.F. *et al.* (1999) *Am. J. Pathol.*, vol. 155, pp. 853-862; Klein, W.L. (2000) in *Molecular Mechanisms of Neurodegenerative Diseases* (Chesselet, M.-F., Ed.), Humana Press; Klein, W.L. *et al.* (2001) *Trends Neurosci.*, vol. 24, pp. 219-224; McLean, C.A. *et al.* (1999) *Ann. Neurol.*, vol. 46, pp. 860-866). Soluble toxic oligomers likely are key factors in plaque-independent A β toxicity. These findings, coupled with antibody data presented here, strongly suggest that behavioral improvement could, at least in part, also be a plaque-independent phenomenon.

Antibodies that target ADDLs may give the ideal specificity. The current neutralizing antibodies, which target novel domains dependent on peptide assembly, are proposed as prototypes for therapeutic vaccination. It is predicted that use of homologous antibodies would combat memory deficits in early stages of AD. By binding to ADDLs, antibodies would protect neural plasticity, which is inhibited experimentally at low ADDL doses (Lambert, M.P. *et al.* (1998) *Proc. Natl. Acad. Sci. USA*, vol. 95, pp. 6448-6453; Wang, H. *et al.* (2000) *Soc. Neurosci. Abstr.*, vol. 26, pp. 1787). In addition, by targeting sub-fibrillar species, the antibodies would eliminate intermediates needed for plaque formation. Independent of their potential direct therapeutic value, the antibodies should be powerful tools to identify toxic domains on oligomer surfaces, thus providing critical molecular insight for development of more traditional therapeutic drugs. Moreover, ADDL-selective antibodies provide a basis for simple high throughput assays to screen libraries for compounds that block toxic oligomerization.

It has been discovered that in neurotoxic samples of amyloid β not only do fibrillar structures exist, but also, unexpectedly, some globular protein structures exist that appear to be responsible for the neurotoxicity. Using novel methods, samples that contain predominantly these soluble globular protein assemblies and no fibrillar structures have been generated as described herein. In heterogeneous samples prepared by various methods, the removal of the larger, fibrillar forms of amyloid β by centrifugation does not remove these soluble globular assemblies of amyloid β in the supernatant fractions. These supernatant fractions exhibit significantly higher neurotoxicity than non-fractionated amyloid β samples aggregated under literature conditions. These novel and unexpected neurotoxic soluble globular forms are referred to herein as amyloid β -derived dementing ligands, amyloid β -derived diffusible ligands (ADDLs), amyloid β soluble non-fibrillar structures, amyloid β oligomeric structures, or simply oligomeric structures. Samples of amyloid β that had been "aged" under standard literature conditions (*e.g.*, Pike *et al.* (1993) *J. Neurosci.*, vol. 13, pp. 1676-1687) for more than three weeks lose their neurotoxicity, even though these samples contain predominantly fibrillar structures with few or no ADDLs. This discovery that the globular ADDLs are neurotoxic is particularly surprising since current thinking holds that it is fibril structures that constitute the toxic form of

amyloid β (Lorenzo *et al.* (1994) *Proc. Natl. Acad. Sci. USA*, vol. 91, pp. 12243-12247; Howlett *et al.* (1995) *Neurodegen.*, vol. 4, pp. 23-32).

ADDLs can be formed *in vitro*. When a solution (*e.g.*, a DMSO solution) containing monomeric amyloid β 1-42 (or other appropriate amyloid β , as further described herein) is diluted into cold tissue culture media (*e.g.*, F12 cell culture media), then allowed to incubate at about 4°C for from about 2 to about 48 hours and centrifuged for about 10 minutes at about 14,000g at a temperature of 4°C, the supernatant fraction contains small, soluble oligomeric globules that are highly neurotoxic, *e.g.*, in neuronal cell and brain slice cultures. The ADDLs also can be formed by co-incubation of amyloid β with certain appropriate agents, *e.g.*, clusterin (a senile plaque protein that also is known as ApoJ), as well as by other methods, as described herein.

Thus, in particular, the present invention pertains to an isolated, soluble, non-fibrillar amyloid β oligomeric structure. The oligomeric structure so isolated does not contain an exogenously added crosslinking agent. The oligomeric structure desirably is stable in the absence of any crosslinker.

Atomic force microscope analysis (AFM) can be carried out as is known in the art and described herein, for instance, using a Digital Instruments Atomic force microscope as described in Example 3. AFM of such a supernatant fraction (*i.e.*, a supernatant fraction in which fibrillar structures have been removed) reveals a number of different size globules (*i.e.*, or different size oligomeric structures) present in the fraction. These globules fall within the range of from about 4.7 to about 11.0 nm, with the major fraction falling within a size range of from about 4.7 nm to about 6.2 nm. There appear to be distinct species of globules falling within this size range and which correspond to specific size oligomeric species such as those indicated by analysis on certain gel electrophoresis systems, as shown in Fig. 2 and Fig. 16. Slight variation in height surface results from how the particular species are seated on the mica surface at the time of AFM analysis. Despite this slight variation however, there appear to be several predominant sizes of globules in the 4.7-6.2 size range, *i.e.*, from about 4.9 nm to about 5.4 nm, and from about 5.7 nm to about 6.2 nm, that constitute about 50% of the oligomeric structures in a typical sample. There also appears to be a distinct size species of globule having dimensions of from about

5.3 nm to about 5.7 nm. Larger globules from about 6.5 nm to about 11.0 nm appear less frequently, but may possess neurotoxic properties similar to the more prevalent, smaller species. It appears that the globules of dimensions of from about 4.7 nm to about 6.2 nm on AFM comprise the pentamer and hexamer form of oligomeric amyloid β ($A\beta$) protein. The AFM size globules of from about 4.2 nm to about 4.7 nm appear to correspond to the $A\beta$ tetramer. The size globules of from about 3.4 nm to about 4.0 nm appear to correspond to trimer. The large globules appear to correspond to oligomeric species ranging in size from about 13 amyloid monomers to about 24 amyloid monomers. The size globules of from about 2.8 nm to about 3.4 nm correspond to dimer (Roher *et al.* (1996) *J. Biol. Chem.*, vol. 271, pp. 20631-20635). The $A\beta$ monomer AFM size ranges from about 0.8 nm to about 1.8 – 2.0 nm. Monomeric and dimeric amyloid β are not neurotoxic in neuronal cell cultures or in the organotypic brain slice cultures.

Thus, the present invention provides an isolated soluble non-fibrillar amyloid β oligomeric structure (*i.e.*, an ADDL) that preferably comprises at from about 3 to about 24 amyloid β protein monomers, especially from about 3 to about 20 amyloid β protein monomers, particularly from about 3 to about 16 amyloid β protein monomers, most preferably from about 3 to about 12 amyloid β protein monomers, and which desirably comprises at from about 3 to about 6 amyloid β protein monomers. As previously described, large globules (less predominant species) appear to correspond to oligomeric species ranging in size from about 13 amyloid β monomers to about 24 amyloid β monomers. Accordingly, the invention provides an isolated soluble non-fibrillar amyloid β oligomeric structure wherein the oligomeric structure preferably comprises trimer, tetramer, pentamer, hexamer, heptamer, octamer, 12-mer, 16-mer, 20-mer or 24-mer aggregates of amyloid β proteins. In particular, the invention provides an isolated soluble non-fibrillar amyloid β protein oligomeric structure wherein the oligomeric structure preferably comprises trimer, tetramer, pentamer, or hexamer aggregates of amyloid β protein. The oligomeric structure of the invention optimally exhibits neurotoxic activity.

The higher order structure of the soluble, non-fibrillar amyloid β protein oligomer structure (*i.e.*, the aggregation of monomers to form the oligomeric structure) desirably can be obtained not only from amyloid β 1-42, but also from

any amyloid β protein capable of stably forming the soluble non-fibrillar amyloid β oligomeric structure. In particular, amyloid β 1-43 also can be employed. Amyloid β 1-42 with biocytin at position 1 also can be employed. Amyloid β (e.g., β 1-42 or β 1-43) with a cysteine at the N-terminus also can be employed.

5 Similarly, A β truncated at the amino terminus (e.g., particularly missing one or more up to the entirety of the sequence of amino acid residues 1 through 8 of A β 1-42 or A β 1-43), or A β (e.g., A β 1-42 or 1-43) having one or two extra amino acid residues at the carboxyl terminus can be employed. By contrast, amyloid β 1-40

10 can transiently form ADDL-like structures which can be toxic, but these structures are not stable and cannot be isolated as aqueous solutions, likely due to the shortened nature of the protein, which limits its ability to form such higher order assemblies in a stable fashion.

Desirably, the isolated soluble non-fibrillar amyloid β oligomeric structure according to the invention comprises globules of dimensions of from about 4.7

15 nm to about 11.0 nm, particularly from about 4.7 nm to about 6.2 nm as measured by atomic force microscopy. Also, preferably the isolated soluble non-fibrillar amyloid β oligomeric structure comprises globules of dimensions of from about 4.9 nm to about 5.4 nm, or from about 5.7 nm to about 6.2 nm, or from about 6.5 nm to about 11.0 nm, as measured by atomic force microscopy. In

20 particular, preferably the isolated soluble non-fibrillar amyloid β oligomeric structure according to the invention is such that wherein from about 30% to about 85%, even more preferably from about 40% to about 75% of the assembly comprises two predominant sizes of globules, namely, of dimensions of from about 4.9 nm to about 5.4 nm, and from about 5.7 nm to about 6.2 nm, as

25 measured by atomic force microscopy. However, it also is desirable that the oligomeric structure comprises AFM size globules of about 5.3 to about 5.7 nm. It is also desirable that the oligomeric structure may comprise AFM size globules of about 6.5 nm to about 11.0 nm.

By non-denaturing gel electrophoresis, the bands corresponding to ADDLs

30 run at about from 26 kD to about 28 kD, and with a separate broad band representing sizes of from about 36 kD to about 108 kD. Under denaturing conditions (e.g., on a 15% SDS-polyacrylamide gel), the ADDLs comprise a band that runs at from about 22 kD to about 24 kD, and may further comprise a band

that runs at about 18 to about 19 kD. Accordingly, the invention preferably provides an isolated soluble non-fibrillar amyloid β oligomeric structure (*i.e.*, ADDL) that has a molecular weight of from about 26 kD to about 28 kD as determined by non-denaturing gel electrophoresis. The invention also preferably
5 provides an isolated soluble non-fibrillar amyloid β oligomeric structure (*i.e.*, ADDL) that runs as a band corresponding to a molecular weight of from about 22 kD to about 24 kD as determined by electrophoresis on a 15% SDS-polyacrylamide gel. The invention further preferably provides an isolated soluble non-fibrillar amyloid β oligomeric structure (*i.e.*, ADDL) that runs as a band
10 corresponding to a molecular weight of from about 18 kD to about 19 kD as determined by electrophoresis on a 15% SDS-polyacrylamide gel.

Also, using a 16.5% tris-tricine SDS-polyacrylamide gel system, additional ADDL bands can be visualized. The increased resolution obtained with this gel system confirms the ability to obtain according to the invention an isolated
15 oligomeric structure having a molecular weight ranging from about 13 kD to about 116 kD, as determined by electrophoresis on a 16.5% tris-tricine SDS-polyacrylamide gel. The ADDL bands appear to correspond to distinct size species. In particular, use of this gel system allows visualization of bands corresponding to trimer with a size of about 13 to about 14 kD, tetramer with a
20 size of about 17 to about 19 kD, pentamer with a size of about 22 kD to about 23 kD, hexamer with a size of about 26 to about 28 kD, heptamer with a size from about 32 kD to 33 kD, and octamer with a size from about 36 kD to about 38 kD, as well as larger soluble oligomers ranging in size from about 12 monomers to about 24 monomers. Thus, the invention desirably provides an isolated
25 oligomeric structure, wherein the oligomeric structure has, as determined by electrophoresis on a 16.5% tris-tricine SDS-polyacrylamide gel, a molecular weight selected from the group consisting of from about 13 kD to about 14 kD, from about 17 kD to about 19 kD, from about 22 kD to about 23 kD, from about 26 kD to about 28 kD, from about 32 kD to about 33 kD, and from about 36 kD to
30 about 38 kD.

The invention further provides a method for preparing the isolated, soluble, non-fibrillar amyloid β oligomeric structure. This method optionally comprises the steps of:

- (a) obtaining a solution of monomeric amyloid β protein;
- (b) diluting the protein solution into an appropriate media;
- (c) incubating the media resulting from step (b) at about 4°C;
- 5 (d) centrifuging the media at about 14,000 g at about 4°C; and
- (e) recovering the supernatant resulting from the centrifugation as containing the amyloid β oligomeric structure.

In step (c) of this method, the solution desirably is incubated for about 2
10 hours to about 48 hours, especially for about 12 hours to about 48 hours, and
most preferably for about 24 hours to about 48 hours. In step (d) of this method,
the centrifugation preferably is carried out for about 5 minutes to about 1 hour,
especially for about 5 minutes to about 30 minutes, and optimally for about 10
minutes. Generally, however, this is just a precautionary measure to remove any
15 nascent fibrillar or protofibrillar structures and may not be necessary, particularly
where long-term stability of the ADDL preparation is not an issue.

The A β protein is diluted in step (b) desirably to a final concentration
ranging from about 5 nM to about 500 μ M, particularly from about 5 μ M to about
300 μ M, especially at about 100 μ M. The "appropriate media" into which the A β
20 protein solution is diluted in step (b) preferably is any media that will support, if
not facilitate, ADDL formation. In particular, F12 media (which is commercially
available as well as easily formulated in the laboratory) is preferred for use in this
method of the invention. Similarly, "substitute F12 media" also desirably can be
employed. Substitute F12 media differs from F12 media that is commercially
25 available or which is formulated in the laboratory. According to the invention,
substitute F12 media preferably comprises the following components: N, N-
dimethylglycine, D-glucose, calcium chloride, copper sulfate pentahydrate, iron(II)
sulfate heptahydrate, potassium chloride, magnesium chloride, sodium chloride,
sodium bicarbonate, disodium hydrogen phosphate, and zinc sulfate
30 heptahydrate.

In particular, synthetic F12 media according to the invention optionally
comprises: N, N-dimethylglycine (from about 600 to about 850 mg/L), D-glucose
(from about 1.0 to about 3.0 g/L), calcium chloride (from about 20 to about 40

mg/L), copper sulfate pentahydrate (from about 15 to about 40 mg/L), iron(II) sulfate heptahydrate (from about 0.4 to about 1.2 mg/L), potassium chloride (from about 160 to about 280 mg/L), magnesium chloride (from about 40 to about 75 mg/L), sodium chloride (from about 6.0 to about 9.0 g/L), sodium bicarbonate
5 (from about 0.75 to about 1.4 g/L), disodium hydrogen phosphate (from about 120 to about 160 mg/L), and zinc sulfate heptahydrate (from about 0.7 to about 1.1 mg/L). Optimally, synthetic F12 media according to the invention comprises: N, N-dimethylglycine (about 766 mg/L), D-glucose (about 1.802 g/L), calcium chloride (about 33 mg/L), copper sulfate pentahydrate (about 25 mg/L), iron(II)
10 sulfate heptahydrate (about 0.8 mg/L), potassium chloride (about 223 mg/L), magnesium chloride (about 57 mg/L), sodium chloride (about 7.6 g/L), sodium bicarbonate (about 1.18 g/L), disodium hydrogen phosphate (about 142 mg/L), and zinc sulfate heptahydrate (about 0.9 mg/L). Further, the pH of the substitute F12 media preferably is adjusted, for instance, using 0.1 M sodium hydroxide,
15 desirably to a pH of about 7.0 to about 8.5, and preferably a pH of about 8.0.

The foregoing method further desirably can be carried out by forming the slowly-sedimenting oligomeric structure in the presence of an appropriate agent, such as clusterin. This is done, for instance, by adding clusterin in step (c), and, as set out in the Examples which follow.

20 Moreover, the invention also provides as described in the Examples, a method for preparing a soluble non-fibrillar amyloid β oligomeric structure according to the invention, wherein the method comprises:

- 25 (a) obtaining a solution of monomeric amyloid β protein, the amyloid β protein being capable of forming the oligomeric structure;
- (b) dissolving the amyloid β monomer in hexafluoroisopropanol;
- (c) removing hexafluoroisopropanol by speed vacuum evaporation to obtain solid peptide;
- (d) dissolving the solid peptide in DMSO to form a DMSO stock
30 solution;
- (e) diluting the stock solution into an appropriate media;
- (f) vortexing; and
- (g) incubating at about 4°C for about 24 hours.

If the ADDLs are prepared by the incorporation of 10% biotinylated amyloid β 1-42 (or other appropriate biotinylated amyloid β protein), they can be utilized in a receptor binding assay using neural cells and carried out, for instance, on a fluorescence activated cell sorting (FACS) instrument, with labeling by a fluorescent avidin conjugate. Alternately, instead of incorporating biotin in the amyloid β protein, another reagent capable of binding the ADDL to form a fluorescently labeled molecule, and which may already be part of a fluorescent-labeled conjugate, can be employed. For instance, the soluble non-fibrillar amyloid β oligomeric structure can be formed such that the amyloid protein includes another binding moiety, with "binding moiety" as used herein encompassing a molecule (such as avidin, streptavidin, polylysine, and the like) that can be employed for binding to a reagent to form a fluorescently-labeled compound or conjugate. The "fluorescent reagent" to which the oligomeric structure binds need not itself fluoresce directly, but instead may merely be capable of fluorescence through binding to another agent. For example, the fluorescent reagent which binds the oligomeric structure can comprise a β amyloid specific antibody (e.g., 6E10), with fluorescence generated by use of a fluorescent secondary antibody.

Along with other experiments, FACSscan analysis of the rat CNS B103 cells was done without and with ADDL incubation. Results of these and further studies confirm that binding to the cell surface is saturable, and brief treatment with trypsin selectively removes a subset of cell surface proteins and eliminates binding of ADDLs. Proteins that are cleavable by brief treatment with trypsin from the surface of B103 cells also prevent ADDL binding to B103 cells or cultured primary rat hippocampal neurons. These results all support that the ADDLs act through a particular cell surface receptor, and that early events mediated by the ADDLs (*i.e.*, events prior to cell killing) can be advantageously controlled (e.g., for treatment or research) by compounds that block formation and activity (e.g., including receptor binding) of the ADDLs.

Thus, the invention provides a method for identifying compounds that modulate (*i.e.*, either facilitate or block) activity (e.g., activity such as receptor binding) of the ADDL. This method preferably comprises:

- 5
- (a) contacting separate cultures of neuronal cells with the oligomeric structure of the invention either in the presence or absence of contacting with the test compound;
 - (b) adding a reagent that binds to the oligomeric structure, the reagent being fluorescent;
 - (c) analyzing the separate cell cultures by fluorescence-activated cell sorting; and
 - (d) comparing the fluorescence of the cultures, with compounds that block activity (*i.e.*, binding to a cell surface protein) of the oligomeric structure being identified as resulting in a reduced fluorescence of the culture, and compounds that facilitate binding to a cell surface protein (*i.e.*, a receptor) being identified as resulting in an increased fluorescence of the culture, as compared to the corresponding culture contacted with the oligomeric structure in the absence of the test compound.
- 10
- 15

Alternately, instead of adding a fluorescent reagent that in and of itself is able to bind the protein complex, the method desirably is carried out wherein the oligomeric structure is formed from amyloid β 1-42 protein (or another amyloid β) prepared such that it comprises a binding moiety capable of binding the fluorescent reagent.

20

Similarly, the method can be employed for identifying compounds that modulate (*i.e.*, either facilitate or block) formation or activity (*e.g.*, binding to a cell surface protein, such as a receptor) of the oligomeric structure comprising:

25

- (a) preparing separate samples of amyloid β that either have or have not been mixed with the test compound;
 - (b) forming the oligomeric structure in the separate samples;
 - (c) contacting separate cultures of neuronal cells with the separate samples;
 - (d) adding a reagent that binds to the oligomeric structure, the reagent being fluorescent;
- 30

- (e) analyzing the separate cell cultures by fluorescence-activated cell sorting; and
- (f) comparing the fluorescence of the cultures, with compounds that block formation or binding to a cell surface protein of the oligomeric structure being identified as resulting in a reduced fluorescence of the culture, and compounds that facilitate formation or binding to a cell surface protein of the oligomeric structure being identified as resulting in an increased fluorescence of the culture, as compared to the corresponding culture contacted with the oligomeric structure in the absence of the test compound.

Further, instead of adding a fluorescent reagent that in and of itself is able to bind the protein complex, the method can be carried out wherein the oligomeric structure is formed from amyloid β protein prepared such that it comprises a binding moiety capable of binding the fluorescent reagent.

The fluorescence of the cultures further optionally is compared with the fluorescence of cultures that have been treated in the same fashion except that instead of adding or not adding test compound prior to formation of the oligomeric structure, the test compound either is or is not added after formation of the oligomeric structure. In this situation, compounds that block formation of the oligomeric structure are identified as resulting in a reduced fluorescence of the culture, and compounds that facilitate formation of the oligomeric structure are identified as resulting in an increased fluorescence of the culture, as compared to the corresponding culture contacted with the oligomeric structure in the absence of the test compound, *only* when the compound is added prior to oligomeric structure.

By contrast, compounds that block binding to a cell surface protein (e.g., a receptor) of the oligomeric structure are identified as resulting in a reduced fluorescence of the culture, and compounds that facilitate binding to a cell surface protein of the oligomeric structure are identified as resulting in an increased fluorescence of the culture, as compared to the corresponding culture contacted with the oligomeric structure in the absence of the test compound, when the compound is added *either prior to or after* oligomeric structure.

In a similar fashion, a cell-based assay, particularly a cell-based enzyme-linked immunosorbent assay (ELISA) can be employed in accordance with the invention to assess ADDL binding activity. In particular, the method can be employed to detect binding of the oligomeric structure to a cell surface protein.

5 This method preferably comprises:

- (a) forming an oligomeric structure from amyloid β protein;
- (b) contacting a culture of neuronal cells with the oligomeric structure;
- (c) adding an antibody (*e.g.*, 6E10) that binds said oligomeric structure,
10 said antibody including a conjugating moiety (*e.g.*, biotin, or other appropriate agent);
- (d) washing away unbound antibody;
- (e) linking an enzyme (*e.g.*, horseradish peroxidase) to said antibody bound to said oligomeric structure by means of said conjugating
15 moiety;
- (f) adding a colorless substrate (*e.g.*, ABTS) that is cleaved by said enzyme to yield a color change; and
- (g) determining said color change (*e.g.*, spectrophotometrically) or the rate of the color change as a measure of binding to a cell surface
20 protein (*e.g.*, a receptor) of said oligomeric structure.

As earlier described, the antibody can be any antibody capable of detecting ADDLs (*e.g.*, an antibody specific for ADDLs or an antibody directed to an exposed site on amyloid β), and the antibody conjugating moiety can be any
25 agent capable of linking a means of detection (*e.g.*, an enzyme). The enzyme can be any moiety (*e.g.*, perhaps even other than a protein) that provides a means of detecting (*e.g.*, color change due to cleavage of a substrate), and further, can be bound (*e.g.*, covalent or noncovalent) to the antibody bound to the oligomeric structure by means of another moiety (*e.g.*, a secondary antibody).
30 Also, preferably according to the invention the cells are adhered to a solid substrate (*e.g.*, tissue culture plastic) prior to the conduct of the assay. It goes without saying that desirably step (b) should be carried out as described herein such that ADDLs are able to bind to cells. Similarly, preferably step (c) should be

carried out for a sufficient length of time (e.g., from about 10 minutes to about 2 hours, desirably for about 30 minutes) and under appropriate conditions (e.g., at about room temperature, preferably with gentle agitation) to allow antibody to bind to ADDLs. Further, appropriate blocking steps can be carried out such as
5 are known to those skilled in the art using appropriate blocking reagents to reduce any nonspecific binding of the antibody. The artisan is familiar with ELISAs and can employ modifications to the assay such as are known in the art.

The assay desirably also can be carried out so as to identify compounds that modulate (*i.e.*, either facilitate or block) formation or binding to a cell surface
10 protein of the oligomeric structure. In this method, as in the prior-described assays for test compounds, the test compound is either added to the ADDL preparation, prior to the contacting of the cells with the ADDLs. This assay thus can be employed to detect compounds that modulate formation of the oligomeric structure (e.g., as previously described). Moreover, the test compound can be
15 added to the ADDL preparation prior to contacting the cells (but after ADDL formation), or to the cells prior to contact with ADDLs. This method (e.g., as previously described) can be employed to detect compounds that modulate ADDL binding to the cell surface. Also, a test compound can be added to the mixture of cells plus ADDLs. This method (e.g., as previously described) can be
20 employed to detect compounds that impact on ADDL-mediated events occurring downstream of ADDL binding to a cell surface protein (e.g., to an ADDL receptor). The specificity of the compounds for acting on an ADDL-mediated downstream effect can be confirmed, for instance, by simply adding the test compound in the absence of any coincubation with ADDLs. Of course, further
25 appropriate controls (e.g., as set forth in the following Examples and as known to those skilled in the art) should be included with all assays.

Similarly, using the methods described herein (e.g., in the Examples), the present invention provides a method for identifying compounds that block formation of the oligomeric structure of the invention, wherein the method
30 desirably comprises:

- (a) preparing separate samples of amyloid β protein that either have or have not been mixed with the test compound;

- (b) forming the oligomeric structure in the separate samples;
- (c) assessing whether any protein assemblies have formed in the separate samples using a method selected from the group consisting of electrophoresis, immunorecognition, and atomic force microscopy; and
- 5 (d) comparing the formation of the protein assemblies in the separate samples, which compounds that block formation of the oligomeric structure being identified as resulting in decreased formation of the oligomeric structure in the sample as compared with a sample in
- 10 which the oligomeric structure is formed in the absence of the test compound.

This information on compounds that modulate (*i.e.*, facilitate or block) formation, activity, or formation and activity, including, but not limited to, binding

15 to a cell surface protein, of the oligomeric structure can be employed in the research and treatment of ADDL-mediated diseases, conditions, or disorders. The methods of the invention can be employed to investigate the activity and neurotoxicity of the ADDLs themselves. For instance, when 20 nL of the ADDL preparation was injected into the hippocampal region of an adult mouse 60-70

20 minutes prior to the conduct of a long-term potentiation (LTP) experiment (see *e.g.*, Namgung *et al.* (1995) *Brain Research*, vol. 689, pp. 85-92), the stimulation phase of the experiment occurred in a manner identical with saline control injections, but the consolidation phase showed a significant, continuing decline in synaptic activity as measured by cell body spike amplitude, over the subsequent

25 2 hours, compared with control animals, in which synaptic activity remained at a level comparable to that exhibited during the stimulation phase. Analysis of brain slices after the experiment indicated that no cell death had occurred. These results, as well as other described in the following Examples, confirm that ADDL treatment compromised the LTP response. This indicates that ADDLs contribute

30 to the compromised learning and memory observed in Alzheimer's disease by interference with neuronal signaling processes, rather than by the induction of nerve cell death.

Additional information on the effects of ADDLs (either in the presence or absence of test compounds that potentially modulate ADDL formation and/or

activity) can be obtained using the further assays according to the invention. For instance, the invention provides a method for assaying the effects of ADDLs that preferably comprises:

- 5
- (a) administering the oligomeric structure to the hippocampus of an animal;
 - (b) applying an electrical stimulus; and
 - (c) measuring the cell body spike amplitude over time to determine the long-term potentiation response.

10

The method optionally is carried out wherein the long-term potentiation response of the animal is compared to the long-term potentiation response of another animal treated in the same fashion except having saline administered instead of oligomeric structure prior to application of the electrical stimulus. This method further can be employed to identify compounds that modulate (*i.e.*,
15 increase or decrease) the effects of the ADDLs, for instance, by comparing the LTP response in animals administered ADDLs either alone, or, in conjunction with test compounds.

Along these lines, the invention provides a method for identifying
20 compounds that modulate the effects of the ADDL oligomeric structure. The method preferably comprises:

- (a) administering either saline or a test compound to the hippocampus of an animal;
- 25 (b) applying an electrical stimulus;
- (c) measuring the cell body spike amplitude over time to determine the long-term potentiation response; and
- (d) comparing the long-term potentiation response of animals having saline administered to the long-term potentiation response of
30 animals having test compound administered.

The method further optionally comprises administering oligomeric structure to the hippocampus either before, along with, or after administering the saline or test compound.

Similarly, the present invention provides a method for identifying compounds that modulate (*i.e.*, either increase or decrease) the neurotoxicity of the ADDL protein assembly, which method comprises:

- 5 (a) contacting separate cultures of neuronal cells with the oligomeric structure either in the presence or absence of contacting with the test compound;
- (b) measuring the proportion of viable cells in each culture; and
- (c) comparing the proportion of viable cells in each culture.

10

Compounds that block the neurotoxicity of the oligomeric structure are identified, for example, as resulting in an increased proportion of viable cells in the culture as compared to the corresponding culture contacted with the oligomeric structure in the absence of the test compound. Compounds that
15 increase the neurotoxicity of the oligomeric structure are identified, for example, as resulting in a reduced portion of viable cells in the culture as compared to the corresponding culture contacted with the oligomeric structure in the presence of the test compound.

The methods of the invention also can be employed in detecting in test
20 materials the ADDLs (*e.g.*, as part of research, diagnosis, and/or therapy). For instance, ADDLs bring about a rapid morphological change in serum-starved B103 cells, and they also activate Fyn kinase activity in these cells within 30 minutes of ADDL treatment (data not shown). ADDLs also induce rapid complex formation between Fyn and focal adhesion kinase (FAK) (Zhang *et al.* (1996)
25 *Neurosci. Lett.*, vol. 211, pp. 1-4), and translocating of several phosphorylated proteins and Fyn-Fak complex to a Triton-insoluble fraction (Berg *et al.* (1997) *J. Neurosci. Res.*, vol. 50, pp. 979-989). This suggests that Fyn and other activated signaling pathways are involved in the neurodegenerative process induced by ADDLs. This has been confirmed by experiments in brain slice cultures from
30 genetically altered mice that lack a functional *fyn* gene, where addition of ADDLs resulted in no increased neurotoxicity compared to vehicle controls.

Therefore, compounds that block one or more of Fyn's function, or Fyn relocalization, namely by impacting on ADDLs, may be important neuroprotective drugs for Alzheimer's disease. Similarly, when ADDLs are added to cultures of

primary astrocytes, the astrocytes become activated and the mRNA for several proteins, including IL-1, inducible nitric oxide synthase, Apo E, Apo J and α 1-antichymotrypsin become elevated. These phenomena desirably are employed in accordance with the invention in a method for detecting in a test material the
5 ADDL protein assembly. Such methods optionally comprise:

- (a) contacting the test material with an antibody (e.g., the 6E10 antibody or another antibody); and
- (b) detecting binding to the oligomeric structure of the antibody.

10

Similarly, the method desirably can be employed wherein:

- (a) the test material is contacted with serum-starved neuroblastoma cells (e.g., B103 neuroblastoma cells); and
- (b) morphological changes in the cells are measured by comparing the morphology of the cells against neuroblastoma cells that have not
15 been contacted with the test material.

15

The method also preferably can be employed wherein:

- (a) the test material is contacted with brain slice cultures; and
- (b) brain cell death is measured as compared against brain slice cultures that have not been contacted with the test material.

20

The method further desirably can be conducted wherein:

25

- (a) the test material is contacted with neuroblastoma cells (e.g., B103 neuroblastoma cells); and
- (b) increases in *fyn* kinase activity are measured by comparing *fyn* kinase activity in the cells against *fyn* kinase activity in neuroblastoma cells that
30 have not been contacted with said test material.

In particular, Fyn kinase activity can be compared making use of a commercially available kit (e.g., Kit #QIA-28 from Oncogene Research Products,

Cambridge, MA) or using an assay analogous to that described in Borowski *et al.* (1994) *J. Biochem.* (Tokyo), vol. 115, pp. 825-829.

In yet another preferred embodiment of the method of detecting ADDLs in test material, the method desirably comprises:

5

- (a) contacting the test material with cultures of primary astrocytes; and
- (b) determining activation of the astrocytes as compared to cultures of primary astrocytes that have not been contacted with the test material.

10

In a variation of this method, the method optionally comprises:

- (a) contacting the test material with cultures of primary astrocytes; and
- (b) measuring in the astrocytes increases in the mRNA for proteins selected from the group consisting of interleukin-1, inducible nitric oxide synthase, Apo E, Apo J, and α 1-antichymotrypsin by comparing the mRNA levels in the astrocytes against the corresponding mRNA levels in cultures of primary astrocytes that have not been contacted with the test material.

15
20

There are, of course, other methods of assay, and further variations of those described above that would be apparent to one skilled in the art, particularly in view of the disclosure herein.

Thus, clearly, the ADDLs according to the present invention have utility *in vitro*. Such ADDLs can be used *inter alia* as a research tool in the study of ADDL binding and interaction within cells and in a method of assaying ADDL activity. Similarly, ADDLs, and studies of ADDL formation, activity and modulation can be employed *in vivo*.

In particular, the compounds identified using the methods of the present invention can be used to treat any one of a number of diseases, disorders, or conditions that result in deficits in cognition or learning (*i.e.*, due to a failure of memory), and/or deficits in memory itself. Such treatment or prevention can be effected by administering compounds that prevent formation and/or activity of the

25
30

ADDLs, or that modulate (*i.e.*, increase or decrease the activity of, desirably as a consequence of impacting ADDLs) the cell agents with which the ADDLs interact (*e.g.*, so-called "downstream" events). Such compounds having ability to impact ADDLs are referred to herein as "ADDL-modulating compounds". ADDL-modulating compounds not only can act in a negative fashion, but also, in some cases preferably are employed to increase the formation and/or activity of the ADDLs.

Desirably, when employed *in vivo*, the method can be employed for protecting an animal against decreases in cognition, learning or memory due to the effects of the ADDL protein assembly. This method comprises administering a compound that blocks the formation or activity of the ADDLs. Similarly, to the extent that deficits in cognition, learning and/or memory accrue due to ADDL formation and/or activity, such deficits can be reversed or restored once the activity (and/or formation) of ADDLs is blocked. The invention thus preferably provides a method for reversing (or restoring) in an animal decreases in cognition, learning or memory due to the effects of an oligomeric structure according to the invention. This method preferably comprises blocking the formation or activity of the ADDLs. The invention thus also desirably provides a method for reversing in a nerve cell decreases in long-term potentiation due to the effects of a soluble non-fibrillar amyloid β oligomeric structure according to the invention (as well as protecting a nerve cell against decrease in long-term potentiation due to the effects of a soluble non-fibrillar amyloid β oligomeric structure), the method comprising contacting the cell with a compound that blocks the formation or activity of the oligomeric structure.

In particular, this method desirably can be applied in the treatment or prevention of a disease, disorder, or condition that manifests as a deficit in cognition, learning and/or memory and which is due to ADDL formation or activity, especially a disease, disorder, or condition selected from the group consisting of Alzheimer's disease, adult Down's syndrome (*i.e.*, over the age of 40 years), and senile dementia.

Also, this method desirably can be applied in the treatment or prevention of early deleterious effects on cellular activity, cognition, learning, and memory that may be apparent prior to the development of the disease, disorder, or

condition itself, and which deleterious effects may contribute to the development of, or ultimately constitute the disease, disorder, or condition itself. In particular, the method preferably can be applied in the treatment or prevention of the early malfunction of nerve cells or other brain cells that can result as a consequence of ADDL formation or activity. Similarly, the method preferably can be applied in the treatment or prevention of focal memory deficits (FMD) such as have been described in the literature (see e.g., Linn *et al.* (1995) *Arch. Neurol.*, vol. 52, pp. 485-490), in the event such FMD are due to ADDL formation or activity. The method further desirably can be employed in the treatment or prevention of ADDL-induced aberrant neuronal signaling, impairment of higher order writing skills (see e.g., Snowdon *et al.* (1996) *JAMA*, vol. 275, pp. 528-532) or other higher order cognitive function, decreases in (or absence of) long-term potentiation, that follows as a consequence of ADDL formation or activity.

According to this invention, "ADDL-induced aberrant neuronal signaling" can be measured by a variety of means. For instance, for normal neuronal signaling (as well as observation of a long-term potentiation response), it appears that among other things, Fyn kinase must be activated, Fyn kinase must phosphorylate the NMDA channel (Miyakawa *et al.* (1997) *Science*, vol. 278, pp. 698-701; Grant (1996) *J. Physiol. Paris*, vol. 90, pp. 337-338), and Fyn must be present in the appropriate cellular location (which can be impeded by Fyn-FAK complex formation, for instance, as occurs in certain cytoskeletal reorganizations induced by ADDL). Based on this, ADDL-induced aberrant neuronal signaling (which is a signaling malfunction that is induced by aberrant activation of cellular pathways by ADDLs) and knowledge thereof can be employed in the methods of the invention, such as would be obvious to one skilled in the art. For instance, ADDL-induced aberrant cell signaling can be assessed (e.g., as a consequence of contacting nerve cells with ADDLs, which may further be conducted in the presence or absence of compounds being tested for ADDL-modulating activity) using any of these measures, or such as would be apparent to one skilled in the art, e.g., Fyn kinase activation (or alteration thereof), Fyn-FAK complex formation (or alteration thereof), cytoskeletal reorganization (or alteration thereof), Fyn kinase subcellular localization (or alteration thereof), Fyn kinase phosphorylation of the NMDA channel (or alteration thereof).

Furthermore, instead of using compounds that are identified using the methods of the invention, compounds known to have particular *in vitro* and *in vivo* effects can be employed to impact ADDLs in the above-described methods of treatment. Namely, amyloid formation can be (but need not necessarily be) modeled as a two-phase process. In the first phase is initiated the production of amyloid precursor protein (*e.g.*, the amyloid precursor protein of 695 amino acids (Kang *et al.* (1987) *Nature*, vol. 325, pp. 733-736) or the 751 amino acid protein (Ponte *et al.* (1988) *Nature*, vol. 331, pp. 525-527) each having within their sequence the β amyloid core protein sequence of approximately 4 kDa identified by Glenner *et al.* (U.S. Patent 4,666,829)). In the second phase occurs amyloid processing and/or deposition into higher molecular weight structures (*e.g.*, fibrils, or any other structure of β amyloid having a molecular weight greater than β amyloid monomer, and including structures that are considerably smaller than plaques and pre-plaques). It is conceivable that some compounds may impact one or both of these phases. For some compounds, a deleterious effect is obtained, but it is not clear whether the locus of inhibition is on protein production, or on amyloid processing and/or deposition.

Thus, relevant to this invention are compounds that act at either the first or second phase, or both phases. In particular, compounds that modulate the second phase have special utility to impact ADDLs and find use in methods of treatment that rely on ADDL modulation. Such compounds that modulate (*e.g.*, block) the deposition of amyloid into higher molecular weight structures include, but are not limited to, compounds that modulate (particularly compounds that impede) the incorporation of β amyloid monomers into higher molecular weight structures, especially fibrils. Accordingly, desirably according to the invention, such compounds that impair incorporation of β amyloid monomers into higher molecular weight structures, particularly compounds that are known to inhibit fibril formation (and thus have been confirmed to inhibit incorporation of β amyloid into higher molecular weight structures), can be employed to exert an inhibitory effect on ADDL formation and/or activity (*i.e.*, by reducing formation of ADDLs), in accordance with the methods of the invention. Of course, it is preferable that prior to such use, the ability of the modulators to impact ADDLs is confirmed, *e.g.*, using the methods of the invention. Such known modulators that desirably

can be employed in the present invention are described as follows, however, other similar modulators also can be employed.

In terms of compounds that act at the second phase, PCT International Application WO 96/39834 and Canadian Application 2222690 pertain to novel peptides capable of interacting with a hydrophobic structural determinant on a protein or peptide for amyloid or amyloid-like deposit formation, thereby inhibiting and structurally blocking the abnormal folding of proteins and peptides into amyloid and amyloid-like deposits. In particular, the '834 application pertains to inhibitory peptides comprising a sequence of from about 3 to about 15 amino acid residues and having a hydrophobic cluster of at least three amino acids, wherein at least one of the residues is a β -sheet blocking amino acid residue selected from Pro, Gly, Asn, and His, and the inhibitory peptide is capable of associating with a structural determinant on the protein or peptide to structurally block and inhibit the abnormal folding into amyloid or amyloid-like deposits.


PCT International Application WO 95/09838 pertains to a series of peptidergic compounds and their administration to patients to prevent abnormal deposition of β amyloid peptide.

PCT International Application WO 98/08868 pertains to peptides that modulate natural β amyloid peptide aggregation. These peptide modulators comprise three to five D-amino acid residues and include at least two D-amino acid residues selected from the group consisting of D-leucine, D-phenylalanine, and D-valine.

Similarly, PCT International Application WO 96/28471 pertains to an amyloid modulator compound that comprises an amyloidogenic protein or peptide fragment thereof (e.g., transthyretin, prion protein, islet amyloid polypeptide, atrial natriuretic factor, kappa light chain, lambda light chain, amyloid A, procalcitonin, cystatin C, β 2-microglobulin, ApoA-1, gelsolin, procalcitonin, calcitonin, fibrinogen, and lysozyme) coupled directly or indirectly to at least one modifying group (e.g., comprises a cyclic, heterocyclic, or polycyclic group, contains a cis-decalin group, contains a cholanyl structure, is a cholyl group, comprises a biotin-containing group, a fluorescein-containing group, etc.) such that the compound modulates the aggregation of natural amyloid proteins or peptides when contacted with these natural amyloidogenic proteins or peptides.

Also, PCT International Application WO 97/21728 pertains to peptides that incorporate the Lys-Leu-Val-Phe-Phe (KVLFF) sequence of amyloid β that is necessary for polymerization to occur. Peptides that incorporate this sequence bind to amyloid β and are capable of blocking fibril formation.


- 5 In terms of non-peptide agents, PCT International Application WO 97/16191 pertains to an agent for inhibiting the aggregation of amyloid protein in animals by administering a 9-acridinone compound having the formula:



10

wherein R¹ and R² are hydrogen, halo, nitro, amino, hydroxy, trifluoromethyl, alkyl, alkoxy, and alkythio; R³ is hydrogen or alkyl; and R⁴ is alkylene-N R⁵ R⁶, wherein R⁵ and R⁶ are independently hydrogen, C₁-C₄ alkyl, or taken together with the nitrogen to which they are attached are piperidyl or pyrrolidinyl, and the pharmaceutically acceptable salts thereof. The disclosed compounds previously were identified as antibacterial and antitumor agents (U.S. Patent 4,626,540) and as antitumor agents (Cholody *et al.* (1990) *J. Med. Chem.*, vol. 33, pp. 49-52; Cholody *et al.* (1992) *J. Med. Chem.*, vol. 35, pp. 378-382).


- 20 PCT International Application WO 97/16194 pertains to an agent for inhibiting the aggregation of amyloid protein in animals by administering a naphthylazo compound having the formula:



wherein R^1 and R^2 independently are hydrogen, alkyl, substituted alkyl, or a
 5 complete heterocyclic ring, R^3 is hydrogen or alkyl, $R^4, R^5, R^6,$ and R^7 are
 substituent groups including, but not limited to hydrogen, halo, alkyl, and alkoxy.

Japanese Patent 9095444 pertains to an agent for inhibiting the
 agglomeration and/or deposition of amyloid protein wherein this agent contains a
 thionaphthalene derivative of the formula:

10



wherein R is a 1-5 carbon alkyl substituted with OH or COOR^4 (optionally
 substituted by aryl, heterocyclyl, COR^5 , CONHR^6 , or cyano; R^4 is H or 1-10
 carbon alkyl, 3-10 carbon alkenyl, 3-10 carbon cyclic alkyl (all optionally
 15 substituted); R^5 and R^6 are optionally substituted aryl or heterocyclyl; R^1 and R^2
 are H , 1-5 carbon alkyl or phenyl; R^3 is hydrogen, 1-5 carbon alkyl or COR^7 ; R^7 is
 OR' , $-\text{R}''$ or $-\text{N}(\text{R}''')_2$; $\text{R}', \text{R}'', \text{R}'''$ is 1-4 carbon alkyl.


Japanese Patent 7309760 and PCT International Application WO
 95/11248 pertain to inhibitors of coagulation and/or deposition of amyloid β

protein which are particular rifamycin derivatives. Japanese Patent 7309759 pertains to inhibitors of coagulation and/or deposition of amyloid β protein which are particular rifamycin SV derivatives. Japanese Patent 7304675 pertains to inhibitors of agglutination and/or precipitation of amyloid β protein which are
 5 particular 3-homopiperazinyl-rifamycin derivatives.

Japanese Patent 7247214 pertains to pyridine derivatives and that salts or prodrugs that can be employed as inhibitors of β -amyloid formation or deposition.


U.S. Patent 5,427,931 pertains to a method for inhibiting deposition of amyloid plaques in a mammal that comprises the administration to the mammal
 10 of an effective plaque-deposition inhibiting amount of protease nexin-2, or a fragment or analog thereof.

In terms of compounds that may act at either the first or second phase (*i.e.*, locus of action is undefined), PCT International Application WO 96/25161 pertains to a pharmaceutical composition for inhibiting production or secretion of
 15 amyloid β protein, which comprises a compound having the formula:



20

wherein ring A is an optionally substituted benzene ring, R represents OR^1 ,



or SR¹, wherein R¹, R² and R³ are the same or different and each is selected from a hydrogen atom, an optionally substituted hydrocarbon group or R² and R³, taken together with the adjacent nitrogen atom, form an optionally substituted nitrogen-containing heterocyclic group, and Y is an optionally substituted alkyl group, or a pharmaceutically acceptable salt thereof, if necessary, with a pharmaceutically acceptable excipient, carrier or diluent. Of course, it is preferred that these and other known modulators (e.g., of the first phase or the second phase) are employed according to the invention. It also is preferred that gossypol and gossypol derivatives be employed. Furthermore, it is contemplated that modulators are employed that have ability to impact ADDL activity (e.g., PCT International Applications WO 93/15112 and 97/26913).

Also, the ADDLs themselves may be applied in treatment. It has been discovered that these novel assemblies described herein have numerous unexpected effects on cells that conceivably can be applied for therapy. For instance, ADDLs activate endothelial cells, which endothelial cells are known, among other things to interact with vascular cells. Along these lines, ADDLs could be employed, for instance, in wound healing. Also, by way of example, Botulinum Toxin Type A (BoTox) is a neuromuscular junction blocking agent produced by the bacterium *Clostridium botulinum* that acts by blocking the release of the neurotransmitter acetylcholine. Botox has proven beneficial in the treatment of disabling muscle spasms, including dystonia. ADDLs themselves theoretically could be applied to either command neural cell function or, to selectively destroy targeted neural cells (e.g., in cases of cancer, for instance of the central nervous system, particularly brain). ADDLs appear further advantageous in this regard given that they have very early effects on cells, and given that their effect on cells (apart from their cell killing effect) appears to be reversible.

As discussed above, the ADDL-modulating compounds of the present invention, compounds known to impact incorporation of amyloid β into higher molecular weight structures, as well as ADDLs themselves, can be employed to contact cells either *in vitro* or *in vivo*. According to the invention, a cell can be any cell, and, preferably, is a eukaryotic cell. A eukaryotic cell is a cell typically that possesses at some stage of its life a nucleus surrounded by a nuclear

membrane. Preferably the eukaryotic cell is of a multicellular species (e.g., as opposed to a unicellular yeast cell), and, even more preferably, is a mammalian (optionally human) cell. However, the method also can be effectively carried out using a wide variety of different cell types such as avian cells, and mammalian
5 cells including but not limited to rodent, primate (such as chimpanzee, monkey, ape, gorilla, orangutan, or gibbon), feline, canine, ungulate (such as ruminant or swine), as well as, in particular, human cells. Preferred cell types are cells formed in the brain, including neural cells and glial cells. An especially preferred cell type according to the invention is a neural cell (either normal or aberrant,
10 e.g., transformed or cancerous). When employed in tissue culture, desirably the neural cell is a neuroblastoma cell.

A cell can be present as a single entity, or can be part of a larger collection of cells. Such a "larger collection of cells" can comprise, for instance, a cell culture (either mixed or pure), a tissue (e.g., neural or other tissue), an organ
15 (e.g., brain or other organs), an organ system (e.g., nervous system or other organ system), or an organism (e.g., mammal, or the like). Preferably, the organs/tissues/cells of interest in the context of the invention are of the central nervous system (e.g., are neural cells).

Also, according to the invention "contacting" comprises any means by
20 which these agents physically touch a cell. The method is not dependent on any particular means of introduction and is not to be so construed. Means of introduction are well known to those skilled in the art, and also are exemplified herein. Accordingly, introduction can be effected, for instance, either *in vitro* (e.g., in an *ex vivo* type method of therapy or in tissue culture studies) or *in vivo*.
25 Other methods also are available and are known to those skilled in the art.

Such "contacting" can be done by any means known to those skilled in the art, and described herein, by which the apparent touching or mutual tangency of the ADDLs and ADDL-modulating compounds and the cell can be effected. For instance, contacting can be done by mixing these elements in a small volume of
30 the same solution. Optionally, the elements further can be covalently joined, e.g., by chemical means known to those skilled in the art, or other means, or preferably can be linked by means of noncovalent interactions (e.g., ionic bonds, hydrogen bonds, Van der Waals forces, and/or nonpolar interactions). In comparison, the cell to be affected and the ADDL or ADDL-modulating compound

need not necessarily be brought into contact in a small volume, as, for instance, in cases where the ADDL or ADDL-modulating compound is administered to a host, and the complex travels by the bloodstream or other body fluid such as cerebrospinal fluid to the cell with which it binds. The contacting of the cell with a
5 ADDL or ADDL-modulating compound sometimes is done either before, along with, or after another compound of interest is administered. Desirably this contacting is done such that there is at least some amount of time wherein the coadministered agents concurrently exert their effects on a cell or on the ADDL.

One skilled in the art will appreciate that suitable methods of administering
10 an agent (*e.g.*, an ADDL or ADDL-modulating compound) of the present invention to an animal for purposes of therapy and/or diagnosis, research or study are available, and, although more than one route can be used for administration, a particular route can provide a more immediate and more effective reaction than another route. Pharmaceutically acceptable excipients also are well-known to
15 those who are skilled in the art, and are readily available. The choice of excipient will be determined in part by the particular method used to administer the agent. Accordingly, there is a wide variety of suitable formulations for use in the context of the present invention. The following methods and excipients are merely exemplary and are in no way limiting.

20 Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms
25 can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients. Lozenge forms can comprise the
30 active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.

An agent of the present invention, alone or in combination with other suitable ingredients, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also can be formulated as pharmaceuticals for non-pressured preparations such as in a nebulizer or an atomizer.

Formulations suitable for parenteral administration are preferred according to the invention and include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

The dose administered to an animal, particularly a human, in the context of the present invention will vary with the agent of interest, the composition employed, the method of administration, and the particular site and organism being treated. However, preferably a dose corresponding to an effective amount of an agent (e.g., an ADDL or ADDL-modulating compound according to the invention) is employed. An "effective amount" is one that is sufficient to produce the desired effect in a host, which can be monitored using several end-points known to those skilled in the art. Some examples of desired effects include, but are not limited to, an effect on learning, memory, LTP response, neurotoxicity, ADDL formation, ADDL cell surface protein (e.g., receptor) binding, antibody binding, cell morphological changes, Fyn kinase activity, astrocyte activation, and changes in mRNA levels for proteins such as interleukin-1, inducible nitric oxide synthase, ApoE, ApoJ, and α 1-antichymotrypsin. These methods described are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan.

Moreover, with particular applications (*e.g.*, either *in vitro* or *in vivo*) the actual dose and schedule of administration of ADDLs or ADDL-modulating compounds can vary depending on whether the composition is administered in combination with other pharmaceutical compositions, or depending on interindividual differences in pharmacokinetics, drug disposition, and metabolism. Similarly, amounts can vary in *in vitro* applications depending on the particular cell type utilized or the means or solution by which the ADDL or ADDL-modulating compound is transferred to culture. One skilled in the art easily can make any necessary adjustments in accordance with the requirements of the particular situation.

With use of certain compounds, it may be desirable or even necessary to introduce the compounds (*i.e.*, agents) as pharmaceutical compositions directly or indirectly into the brain. Direct techniques include, but are not limited to, the placement of a drug delivery catheter into the ventricular system of the host, thereby bypassing the blood-brain barrier. Indirect techniques include, but are not limited to, the formulation of the compositions to convert hydrophilic drugs into lipid-soluble drugs using techniques known in the art (*e.g.*, by blocking the hydroxyl, carboxyl, and primary amine groups present on the drug) which render the drug able to cross the blood-brain barrier. Furthermore, the delivery of hydrophilic drugs can be improved, for instance, by intra-arterial infusion of hypertonic solutions (or other solutions) which transiently open the blood brain barrier.

The foregoing descriptions (as well as those which follow) are exemplary only. Other applications of the method and constituents of the present invention will be apparent to one skilled in the art. Thus, the following examples further illustrate the present invention but, of course, should not be construed as in any way limiting the scope.

Example 1

Preparation of Amyloid β -Oligomers

According to the invention, ADDLs were prepared by dissolving 1 mg of solid amyloid β 1-42 (*e.g.*, synthesized as described in Lambert *et al.* (1994) *J.*

Neurosci. Res., vol. 39, pp. 377-395) in 44 μL of anhydrous DMSO. This 5 mM solution then was diluted into cold (4°C) F12 media (Gibco BRL, Life Technologies, Gaithersburg, Md) to a total volume of 2.20 mL (50-fold dilution), and vortexed for about 30 seconds. The mixture was allowed to incubate at from about 0°C to about 8°C for about 24 hours, followed by centrifugation at 14,000g for about 10 minutes at about 4°C . The supernatant was diluted by factors of 1:10 to 1:10,000 into the particular defined medium, prior to incubation with brain slice cultures, cell cultures or binding protein preparations. In general, however, ADDLs were formed at a concentration of $\text{A}\beta$ protein of 100 μM . Typically, the highest concentration used for experiments is 10 μM and, in some cases, ADDLs (measured as initial $\text{A}\beta$ concentration) were diluted (*e.g.*, in cell culture media) to 1 nM. For analysis by atomic force microscopy (AFM), a 20 μL aliquot of the 1:100 dilution was applied to the surface of a freshly cleaved mica disk and analyzed. Other manipulations were as described as follows, or as is apparent.

Alternately, ADDL formation was carried out as described above, with the exception that the F12 media was replaced by a buffer (*i.e.*, "substitute F12 media") containing the following components: N, N-dimethylglycine (766 mg/L), D-glucose (1.802 g/L), calcium chloride (33 mg/L), copper sulfate pentahydrate (25 mg/L), iron(II) sulfate heptahydrate (0.8 mg/L), potassium chloride (223 mg/L), magnesium chloride (57 mg/L), sodium chloride (7.6 g/L), sodium bicarbonate (1.18 g/L), disodium hydrogen phosphate (142 mg/L), and zinc sulfate heptahydrate (0.9 mg/L). The pH of the buffer was adjusted to 8.0 using 0.1 M sodium hydroxide.

25

Example 2

Crosslinking of Amyloid β Oligomers

Glutaraldehyde has been successfully used in a variety of biochemical systems. Glutaraldehyde tends to crosslink proteins that are directly in contact, as opposed to nonspecific reaction with high concentrations of monomeric protein. In this example, glutaraldehyde-commanded crosslinking of amyloid β was investigated.

Oligomer preparation was carried out as described in Example 1, with use of substitute F12 media. The supernatant that was obtained following centrifugation (and in some cases, fractionation) was treated with 0.22 mL of a 25% aqueous solution of glutaraldehyde (Aldrich, St. Louis, MO), followed by 5 0.67 mL of 0.175 M sodium borohydride in 0.1 M NaOH (according to the method of Levine, *Neurobiology of Aging*, 1995). The mixture was stirred at 4°C for 15 minutes and was quenched by addition of 1.67 mL of 20% aqueous sucrose. The mixture was concentrated 5 fold on a SpeedVac and dialyzed to remove components smaller than 1 kD. The material was analyzed by SDS PAGE. Gel 10 filtration chromatography was carried according to the following: Superose 75PC 3.2/3.0 column (Pharmacia, Upsala, Sweden) was equilibrated with filtered and degassed 0.15% ammonium hydrogen carbonate buffer (pH=7.8) at a flow rate of 0.02 mL/min over the course of 18 h at room temperature. The flow rate was changed to 0.04 mL/min and 20 mL of solvent was eluted. 50 microliters of 15 reaction solution was loaded on to the column and the flow rate was resumed at 0.04 mL/min. Compound elution was monitored via UV detection at 220 nm, and 0.5-1.0 mL fractions were collected during the course of the chromatography. Fraction No. 3, corresponding to the third peak of UV absorbance was isolated and demonstrated by AFM to contain globules 4.9 +/- 0.8 nm (by width analysis). 20 This fraction was highly neurotoxic when contacted with brain slice neurons, as described in the examples which follow.

Example 3

Size Characterization of ADDLs

25

This example sets forth the size characterization of ADDLs formed as in Example 1 using a variety of methods (e.g., native gel electrophoresis, SDS-polyacrylamide gel electrophoresis, AFM, field flow fractionation, immunorecognition, and the like).

30

AFM was carried out essentially as described previously (e.g., Stine *et al.* (1996) *J. Protein Chem.*, vol. 15, pp. 193-203). Namely, images were obtained using a Digital Instruments (Santa Barbara, CA) Nanoscope IIIa Multimode Atomic force microscope using a J-scanner with xy range of 150 μ . Tapping

Mode was employed for all images using etched silicon TESP Nanoprobes (Digital Instruments). AFM data is analyzed using the Nanoscope IIIa software and the IGOR Pro™ waveform analysis software. For AFM analysis, 4 μ scans (i.e., assessment of a 4 μm x 4 μm square) were conducted. Dimensions reported herein were obtained by section analysis, and where width analysis was employed, it is specified as being a value obtained by width analysis. Section and width analysis are in separate analysis modules in the Nanoscope IIIa software. Generally, for ADDL analysis, there is a systematic deviation between the sizes obtained by section analysis and those obtained by width analysis. Namely, for a 4 μ scan, section analysis yields heights that are usually about 0.5 nm taller, thus resulting in a deviation of about 0.5 nm in the values obtained for the sizes of the globules.

Analysis by gel electrophoresis was carried out on 15% polyacrylamide gels and visualized by Coomassie blue staining. ADDLs were resolved on 4-20% tris-glycine gels under non-denaturing conditions (Novex). Electrophoresis was performed at 20 mA for approximately 1.5 hours. Proteins were resolved with SDS-PAGE as described in Zhang *et al.* (1994) *J. Biol. Chem.*, vol. 269, pp. 25247-25250. Protein was then visualized using silver stain (e.g., as described in Sherchenko *et al.* (1996) *Anal. Chem.*, vol. 68, pp. 850-858). Gel proteins from both native and SDS gels were transferred to nitrocellulose membranes according to Zhang *et al.* (*J. Biol. Chem.*, vol. 269, pp. 25247-50 (1994)). Immunoblots were performed with biotinylated 6E10 antibody (Senetac, Inc., St. Louis, MO) at 1:5000 and visualized using ECL (Amersham). Typically, gels were scanned using a densitometer. This allowed provision of the computer-generated images of the gels (e.g., versus photographs of the gels themselves).

Size characterization of ADDLs by AFM section analysis (e.g., as described in Stine *et al.* (1996) *J. Protein Chem.*, vol. 15, pp. 193-203) or width analysis (Nanoscope III software) indicated that the predominant species were globules of about 4.7 nm to about 6.2 nm along the z-axis. Comparison with small globular proteins ($A\beta$ 1-40 monomer, aprotinin, bFGF, carbonic anhydrase) suggested that ADDLs had mass between 17-42 kD. What appear to be distinct species can be recognized. These appear to correspond to globules of dimensions of from about 4.9 nm to about 5.4 nm, from about 5.4 nm to about 5.7

nm, and from about 5.7 nm to about 6.2 nm. The globules of dimensions of about 4.9-5.4 nm and 5.7-6.2 nm appear to comprise about 50% of globules.

In harmony with the AFM analysis, SDS-PAGE immunoblots of ADDLs identified A β oligomers of about 17 kD to about 22 kD, with abundant 4 kD monomer present, presumably a breakdown product. Consistent with this interpretation, non-denaturing polyacrylamide gels of ADDLs show scant monomer, with a primary band near 30 kD, a less abundant band at ~17 kD, and no evidence of fibrils or aggregates. Computer-generated images of a silver stained native gel and a Coomassie stained SDS-polyacrylamide gel are set out in Fig. 1 and Fig. 2, respectively. The correspondence between the SDS and non-denaturing gels confirms that the small oligomeric size of ADDLs was not due to detergent action. Oligomers seen in ADDL preparations were smaller than clusterin (Mr 80 kD, 40 kD in denatured gels), as expected from use of low clusterin concentrations (1/40 relative to A β , which precluded association of A β as 1:1 A β -clusterin complexes).

An ADDL preparation according to the invention was fractionated on a Superdex 75 column (Pharmacia, Superose 75PC 3.2/3.0 column). The fraction comprising the ADDLs was the third fraction of UV absorbance eluting from the column and was analyzed by AFM and SDS-polyacrylamide gel electrophoresis. A representative AFM analysis of fraction 3 is depicted in Fig. 3. Fractionation resulted in greater homogeneity for the ADDLs, with the majority of the globules having dimensions of from about 4.9 nm to about 5.4 nm. SDS-polyacrylamide gel electrophoresis of the fraction demonstrated a heavy lower band corresponding to the monomer/dimer form of A β . As also observed for the non-fractionated preparation of ADDLs, this appears to be a breakdown product of the ADDLs. Heavier loading of the fraction revealed a larger-size broad band (perhaps a doublet). This further confirms the stability of the non-fibrillar oligomeric A β structures to SDS.

30

Example 4

Clusterin Treatment of Amyloid β

Although it has been proposed that fibrillar structures represent the toxic

form of $A\beta$ (Lorenzo *et al.* (1994) *Proc. Natl. Acad. Sci. USA*, vol. 91, pp. 12243-12247; Howlett *et al.* (1995) *Neurodegen.*, vol. 4, pp. 23-32), novel neurotoxins that do not behave as sedimentable fibrils will form when $A\beta$ 1-42 is incubated with low doses of clusterin, which also is known as "Apo J" (Oda *et al.* (1995) *Exper. Neurol.*, vol. 136, pp. 22-31; Oda *et al.* (1994) *Biochem. Biophys. Res. Commun.*, vol. 204, pp. 1131-1136). To test if these slowly sedimenting toxins might still contain small or nascent fibrils, clusterin-treated $A\beta$ preparations were examined by atomic force microscopy.

Clusterin treatment was carried out as described in Oda *et al.* (*Exper. Neurol.*, vol. 136, pp. 22-31 (1995)) basically by adding clusterin in the incubation described in Example 1. Alternatively, the starting $A\beta$ 1-42 could be dissolved in 0.1 N HCl, rather than DMSO, and this starting $A\beta$ 1-42 could even have fibrillar structures at the outset. However, incubation with clusterin for 24 hours at room temperature of 37°C resulted in preparations that were predominantly free of fibrils, consistent with their slow sedimentation. This was confirmed by experiments showing that fibril formation decreases as the amount of clusterin added increases.

The preparations resulting from clusterin treatment exclusively comprised small globular structures approximately 5-6 nm in size as determined by AFM analysis of ADDLs fractionated on a Superdex 75 gel column. Equivalent results were obtained by conventional electron microscopy. In contrast, $A\beta$ 1-42 that had self-associated under standard conditions (Snyder *et al.* (1994) *Biophys. J.*, vol. 67, pp. 1216-1228) in the absence of clusterin showed primarily large, non-diffusible fibrillar species. Moreover, the resultant ADDL preparations were passed through a Centricon 10 kD cut-off membrane and analyzed on as SDS-polyacrylamide gradient gel. As can be seen in Fig. 4, only the monomer passes through the Centricon 10 filter, whereas ADDLs are retained by the filter. Monomer found after the separation could only be formed from the larger molecular weight species retained by the filter.

These results confirm that toxic ADDL preparations comprise small fibril-free oligomers of $A\beta$ 1-42, and that ADDLs can be obtained by appropriate clusterin treatment of amyloid β .

Example 5

Physiological Formation of ADDLs

The toxic moieties in Example 4 could comprise rare structures that
5 contain oligomeric A β and clusterin. Whereas Oda *et al.* (*Exper. Neurol.*, vol.
136, pp. 22-31 (1995)) reported that clusterin was found to increase the toxicity of
A β 1-42 solutions, others have found that clusterin at stoichiometric levels
protects against A β 1-40 toxicity (Boggs *et al.* (1997) *J. Neurochem.*, vol. 67, pp.
1324-1327). Accordingly, ADDL formation in the absence of clusterin further was
10 characterized in this Example.

When monomeric A β 1-42 solutions were maintained at low temperature in
an appropriate media, formation of sedimentable A β fibrils was almost completely
blocked. A β , however, did self-associate in these low-temperature solutions,
forming ADDLs essentially indistinguishable from those chaperoned by clusterin.
15 Finally, ADDLs also formed when monomeric A β solutions were incubated at 37
degrees in brain slice culture medium but at very low concentration (50 nM),
indicating a potential to form physiologically. All ADDL preparations were
relatively stable and showed no conversion to fibrils during the 24 hour tissue
culture experiments.

20 These results confirm that ADDLs form and are stable under physiological
conditions and suggest that they similarly can form and are stable *in vivo*.

Example 6

ADDLs are Diffusible, Extremely Potent CNS Neurotoxins

25

Whether ADDLs were induced by clusterin, low temperature, or low A β
concentration, the stable oligomers that formed were potent neurotoxins. Toxicity
was examined in organotypic mouse brain slice cultures, which provided a
physiologically relevant model for mature CNS. Brain tissue was supported at the
30 atmosphere-medium interface by a filter in order to maintain high viability in
controls.

For these experiments, brain slices were obtained from mouse strains B6
129 F2 and JR 2385 (Jackson Laboratories, Bar Harbor, ME) and cultured as

previously described (Stoppini *et al.* (1991) *J. Neurosci. Meth.*, vol. 37, pp. 173-182), with modifications. Namely, an adult mouse was sacrificed by carbon dioxide inhalation, followed by rapid decapitation. The head was immersed in cold, sterile dissection buffer (94 mL Gey's balanced salt solution, pH 7.2, 5 supplemented with 2 mL 0.5M MgCl₂, 2 ml 25% glucose, and 2 mL 1.0 M HEPES), after which the brain was removed and placed on a sterile Sylgard-coated plate. The cerebellum was removed and a mid-line cut was made to separate the cerebral hemispheres. Each hemisphere was sliced separately. The hemisphere was placed with the mid-line cut down and a 30 degree slice from the dorsal side 10 was made to orient the hemisphere. The hemisphere was glued cut side down on the plastic stage of a Campden tissue chopper (previously wiped with ethanol) and immersed in ice cold sterile buffer. Slices of 200 µm thickness were made from a lateral to medial direction, collecting those in which the hippocampus was visible.

15 Each slice was transferred with the top end of a sterile pipette to a small petri dish containing Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal calf serum, 2% S/P/F (streptomycin, penicillin, and fungizone; Life Technologies (Gibco, BRL), Gaithersburg, MD), observed with a microscope to verify the presence of the hippocampus, and placed on a Millicell-CM insert 20 (Millipore) in a deep well tissue culture dish (Falcon, 6-well dish). Each well contained 1.0 mL of growth medium, and usually two slices were on each insert. Slices were placed in a incubator (6% CO₂, 100% humidity) overnight. Growth medium was removed and wells were washed with 1.0 mL warm Hanks BSS (Gibco, BRL, Life Technologies). Defined medium (DMEM, N2 supplements, 25 SPF, *e.g.*, as described in Bottenstein *et al.* (1979) *Proc. Natl. Acad. Sci.*, vol. 76, pp. 514-517) containing the amyloid β oligomers, with or without inhibitor compounds, was added to each well and the incubation was continued for 24 hours.

30 Cell death was measured using the LIVE/DEAD[®] assay kit (Molecular Probes, Eugene, OR). This a dual-label fluorescence assay in which live cells are detected by the presence of an esterase that cleaves calcein-AM to calcein, resulting in a green fluorescence. Dead cells take up ethidium homodimer, which intercalates with DNA and has a red fluorescence. The assay was carried out according to the manufacturer's directions at 2 µM ethidium homodimer and 4 µM

calcein. Images were obtained within 30 minutes using a Nikon Diaphot microscope equipped with epifluorescence. The MetaMorph image analysis system (Universal Imaging Corporation, Philadelphia, PA) was used to quantify the number and/or area of cells showing green or red fluorescence.

5 For these experiments, ADDLs were present for 24 hours at a maximal 5 μM dose of total $A\beta$ (*i.e.*, total $A\beta$ was never more than 5 μM in any ADDL experiment). Cell death, as shown by "false yellow staining", was almost completely confined to the stratum pyramidale (CA 3-4) and dentate gyrus (DG) suggesting strongly that principal neurons of the hippocampus (pyramidal and
10 granule cells, respectively) are the targets of ADDL-induced toxicity. Furthermore, glia viability is unaffected by a 24 hour ADDL treatment of primary rat brain glia, as determined by trypan blue exclusion and MTT assay (Finch *et al.*, unpublished). Dentate gyrus (DG) and CA3 regions were particularly sensitive and showed ADDL-evoked cell death in every culture obtained from animals
15 aged P20 (weanlings) to P84 (young adult). Up to 40% of the cells in this region die following chronic exposure to ADDLs. The pattern of neuronal death was not identical to that observed for NMDA, which killed neurons in DG and CA1 but spared CA3.

Some cultures from hippocampal DG and CA3 regions of animals more
20 than 20 days of age were treated with conventional preparations of fibrillar $A\beta$. Consistent with the non-diffusible nature of the fibrils, no cell death (yellow staining) was evident even at 20 μM . The staining pattern for live cells in this culture verified that the CA3/dentate gyrus region of the hippocampus was being examined. The extent of cell death observed after conventional $A\beta$ treatment (*i.e.*,
25 fibrillar $A\beta$ preparations) was indistinguishable from negative controls in which cultures were given medium, or medium with clusterin supplement. In typical controls, cell death was less than 5%. In fact, high viability in controls could be found even in cultures maintained several days beyond a typical experiment, which confirms that cell survival was not compromised by standard culture
30 conditions.

A dose-response experiment was carried out to determine the potency of ADDLs in evoking cell death. Image analysis was used to quantify dead cell and live cell staining in fields containing the DG/CA3 areas. Fig. 5 illustrates the % dead cells verses ADDL concentration measured as initial amyloid β 1-42

concentration (nM). Because of the difficulties of quantifying brain slices, the results are not detailed enough to determine the EC50 with precision. However, as can be seen in Fig. 5, even after 1000-fold dilution (~5 nM A β), ADDL-evoked cell death was more than 20%. Toxicity was observed even with 0.3 nM ADDLs.

5 This contrasts with results obtained with conventionally aged A β , which is toxic to neurons in culture at about 20 to about 50 μ M. These data show that ADDLs are effective at doses approximately 1,000-10,000-fold smaller than those used in fibrillar A β experiments.

These data from hippocampal slices thus confirm the ultratoxic nature of ADDLs. Furthermore, because ADDLs had to pass through the culture-support filter to cause cell death, the results validate that ADDLs are diffusible, consistent with their small oligomeric size. Also, the methods set forth herein can be employed as an assay for ADDL-mediated changes in cell viability. In particular, the assay can be carried out by co-incubating or co-administering along with the ADDLs agents that potentially may increase or decrease ADDL formation and/or activity. Results obtained with such co-incubation or co-administration can be compared to results obtained with inclusion of ADDLs alone.

10
15

Example 7

20 *MTT Oxidative Stress Toxicity Assay - PC12 Cells*

This example sets forth an assay that can be employed to detect an early toxicity change in response to amyloid β oligomers.

For these experiments, PC12 cells were passaged at 4×10^4 cells/well on a 96-well culture plate and grown for 24 hours in DMEM + 10% fetal calf serum + 1% S/P/F (streptomycin, penicillin, and fungizone). Plates were treated with 200 μ g/mL poly-L-lysine for 2 hours prior to cell plating to enhance cell adhesion. One set of six wells was left untreated and fed with fresh media, while another set of wells was treated with the vehicle control (PBS containing 10% 0.01 N HCl, aged o/n at RT). Positive controls were treated with triton (1%) and Na Azide (0.1%) in normal growth media. Amyloid β oligomers prepared as described in Example 1, or obtained upon co-incubation with clusterin, with and without inhibitor compounds present, were added to the cells for 24 hours. After the 24 hour

25
30

incubation, MTT (0.5 mg/mL) was added to the cells for 2.5 hours (11 μ L of 5 mg/ml stock solubilized in PBS into 100 μ L of media). Healthy cells reduce the MTT into a formazan blue colored product. After the incubation with MTT, the media was aspirated and 100 μ L of 100% DMSO was added to lyse the cells and dissolve the blue crystals. The plate was incubated for 15 min at RT and read on a plate reader (ELISA) at 550 nm.

The results of one such experiment are depicted in Fig. 6. As can be seen from this figure, control cells not exposed to ADDLs ("Cont."), cells exposed to clusterin alone ("Apo J"), and cells exposed to monomeric $A\beta$ (" $A\beta$ ") show no cell toxicity. By contrast, cells exposed to amyloid β co-aggregated with clusterin and aged one day (" $A\beta$:Apo J") show a decrease in MTT reduction, evidencing an early toxicity change. The lattermost amyloid preparations were confirmed by AFM to lack amyloid fibrils.

Results of this experiment thus confirm that that ADDL preparations obtained from co-aggregation of $A\beta$ mediated by clusterin have enhanced toxicity. Moreover, the results confirm that the PC 12 oxidative stress response can be employed as an assay to detect early cell changes due to ADDLs. The assay can be carried out by co-incubating or co-administering along with the ADDLs agents that potentially may increase or decrease ADDL formation and/or activity. Results obtained with such co-incubation or co-administration can be compared to results obtained with inclusion of ADDLs alone.

Example 8

MTT Oxidative Stress Toxicity Assay - HN2 Cells

This example sets forth a further assay of ADDL-mediated cell changes. Namely, the MTT oxidative stress toxicity assay presented in the preceding example can be carried out with HN2 cells instead of PC12 cells. Other appropriate cells similarly can be employed.

For this assay, HN2 cells were passaged at 4×10^4 cells/well on a 96-well culture plate and grown for 24 hours in DMEM + 10% fetal calf serum + 1% S/P/F (streptomycin, penicillin, and fungizone). Plates were treated with 200 μ g/mL poly l-lysine for 2 hours prior to cell plating to enhance cell adhesion. The cells were differentiated for 24-48 hours with 5 μ M retinoic acid and growth was further

inhibited with 1% serum. One set of wells was left untreated and given fresh media. Another set of wells was treated with the vehicle control (0.2% DMSO). Positive controls were treated with triton (1%) and sodium azide (0.1%). Amyloid β oligomers prepared as described in example 1, with and without inhibitor compounds present, were added to the cells for 24 hours. After the 24 hour incubation, MTT (0.5 mg/mL) was added to the cells for 2.5 hours (11 μ L of 5 mg/mL stock into 100 μ L of media). After the incubation with MTT, the media was aspirated and 100 μ L of 100% DMSO is added to lyse the cells and dissolve the blue crystals. The plate was incubated for 15 minutes at RT and read on a plate reader (ELISA) at 550 nm.

This assay similarly can be carried out by co-incubating or co-administering along with the ADDLs agents that potentially may increase or decrease ADDL formation and/or activity. Results obtained with such co-incubation or co-administration can be compared to results obtained with inclusion of ADDLs alone.

Example 9

Cell Morphology by Phase Microscopy

This example sets forth yet another assay of ADDL-mediated cell changes – assay of cell morphology by phase microscopy.

For this assay, cultures were grown to low density (50-60% confluence). To initiate the experiment, the cells were serum-starved in F12 media for 1 hour. Cells were then incubated for 3 hours with amyloid β oligomers prepared as described in example 1, with and without inhibitor compounds added to the cells, for 24 hours. After 3 hours, cells were examined for morphological differences or fixed for immunofluorescence labeling. Samples were examined using the MetaMorph Image Analysis system and an MRI video camera (Universal Imaging, Inc.).

Results of such assays are presented in the examples which follow. In particular, the assay can be carried out by co-incubating or co-administering along with the ADDLs agents that potentially may increase or decrease ADDL formation and/or activity. Results obtained with such co-incubation or co-

administration can be compared to results obtained with inclusion of ADDLs alone.

Example 10

5 *FACScan Assay for Binding of ADDLs to Cell Surfaces*

Because cell surface receptors recently have been identified on glial cells for conventionally prepared $A\beta$ (Yan *et al.* (1996) *Nature*, vol. 382, pp. 685-691; El Khoury *et al.* (1996) *Nature*, vol. 382, pp. 716-719), and because neuronal
10 death at low ADDL doses suggested possible involvement of signaling mechanisms, experiments were undertaken to determine if specific cell surface binding sites on neurons exist for ADDLs.

For flow cytometry, cells were dissociated with 0.1% trypsin and plated at least overnight onto tissue culture plastic at low density. Cells were removed with
15 cold phosphate buffered saline (PBS) /0.5 mM EDTA, washed three times and resuspended in ice-cold PBS to a final concentration of 500,000 cells/mL. Cells were incubated in cold PBS with amyloid β oligomers prepared as described in Example 1, except that 10% of the amyloid β is an amyloid β 1-42 analog containing biocytin at position 1 replacing aspartate. Oligomers with and without
20 inhibitor compounds present were added to the cells for 24 hours. The cells were washed twice in cold PBS to remove free, unbound amyloid β oligomers, resuspended in a 1:1,000 dilution of avidin conjugated to fluorescein, and incubated for one hour at 4°C with gentle agitation. Alternately, amyloid β -specific antibodies and fluorescent secondary antibody were employed instead of
25 avidin, eliminating the need to incorporate 10% of the biotinylated amyloid β analog. Namely, biotinylated 6E10 monoclonal antibody (1 μ L Senetec, Inc., St. Louis, Missouri) was added to the cell suspension and incubated for 30 minutes. Bound antibody was detected after pelleting cells and resuspending in 500 μ L PBS, using FITC-conjugated streptavidin (1:500, Jackson Laboratories) for 30
30 minutes.

Cells were analyzed by a Becton-Dickenson Fluorescence Activated Cell Scanner (FACScan). 10,000 or 20,000 events typically were collected for both forward scatter (size) and fluorescence intensity, and the data were analyzed by

Consort 30 software (Becton-Dickinson). Binding was quantified by multiplying mean fluorescence by total number of events, and subtracting value for background cell fluorescence in the presence of 6E10 and FITC.

For these experiments, FACScan analysis was done to compare ADDL immunoreactivity in suspensions of log-phase yeast cells (a largely carbohydrate surface) and of the B103 CNS neuronal cell line (Schubert *et al.* (1974) *Nature*, vol. 249, pp. 224-227). For B103 cells, addition of ADDLs caused a major increase in cell associated fluorescence, as shown in Fig. 7. Trypsin treatment of the B103 cells for 1 minute eliminated ADDL binding. In contrast, control yeast cells (data not shown) demonstrated no ADDL binding, verifying the selectivity of ADDLs for proteins present on the cell surface. Suspensions of hippocampal cells (trypsinized tissue followed by a two-hour metabolic recovery) also bound ADDLs, but with a reduced number of binding events compared with the B103 cells, as evidenced by the reduced fluorescence intensity of the labelled peak. This appears in Fig. 8 as a leftward shifting of the labelled peak.

These results thus suggest that the ADDLs exert their effects by binding to a specific cell surface receptor. In particular, the trypsin sensitivity of B103 cells showed that their ADDL binding sites were cell surface proteins and that binding was selective for a subset of particular domains within these proteins.

Moreover, the present assay can also be employed as an assay for ADDL-mediated cell binding. In particular, the assay can be carried out by co-incubating or co-administering along with the ADDLs agents that potentially may increase or decrease ADDL formation and/or activity. Results obtained with such co-incubation or co-administration can be compared to results obtained with inclusion of ADDLs alone.

Example 11

Inhibition of ADDL Formation by Gossypol

This example sets forth the manner in which ADDL formation can be inhibited using, for instance, gossypol.

For these experiments, ADDLs were prepared as described in Example 1. Gossypol (Aldrich) was added to a concentration of 100 μ M during the incubation

of the A β protein to form ADDLs. The resulting preparation was assessed for neurotoxicity using the LIVE/DEAD® assay kit as previously described. The amount of cell death that occurred after 24 hours of exposure to the gossypol/ADDL preparation was less than 5%. This is comparable to the level of toxicity obtained for a corresponding DMSO control preparation (*i.e.*, 6%), or a gossypol control preparation that did not contain any ADDLs (*i.e.*, 4%).

These results thus confirm that compounds such as gossypol can be employed to inhibit ADDL formation.

10

Example 12

Inhibition of ADDL Binding by Tryptic Peptides

Because B103 cell trypsinization was found to block subsequent ADDL binding, experiments were done as set forth in this example to test if tryptic fragments released from the cell surface retard ADDL binding activity.

Tryptic peptides were prepared using confluent B103 cells from four 100 mm dishes. Medium was collected after a 3 minute trypsinization (0.025%, Life Technologies), trypsin-chymotrypsin inhibitor (Sigma, 0.5 mg/mL in Hank's Buffered Saline) was added, and cells were removed via centrifugation at 500 x g for 5 minutes. Supernatant (~12 mL) was concentrated to approximately 1.0 mL using a Centricon 3 filter (Amicon), and was frozen after the protein concentration was determined. For blocking experiments, sterile concentrated tryptic peptides (0.25 mg/mL) were added to the organotypic brain slice or to the suspended B103 cells in the FACs assay at the same time as the ADDLs were added.

In FACScan assays, tryptic peptides released into the culture media (0.25 mg/mL) inhibited ADDL binding by > 90% as shown in Fig. 9. By comparison, control cells exposed to BSA, even at 100mg/mL, had no loss of binding. Tryptic peptides, if added after ADDLs were already attached to cells, did not significantly lower fluorescence intensities. This indicates that the peptides did not compromise the ability of the assay to quantify bound ADDLs. Besides blocking ADDL binding, the tryptic peptides also were antagonists of ADDL-evoked cell death. Namely, as shown in Fig. 9, addition of tryptic peptides resulted in a 75% reduction in cell death, $p < 0.002$.

These data confirm that particular cell surface proteins mediate ADDL binding, and that solubilized tryptic peptides from the cell surface provide neuroprotective, ADDL-neutralizing activity. Moreover, the present assay can also be employed as an assay for agents that mediate ADDL cell binding or ADDL effects on cell activity. In particular, the assay can be carried out by co-incubating or co-administering along with the ADDLs agents that potentially may increase or decrease ADDL formation and/or activity. Results obtained with such co-incubation or co-administration can be compared to results obtained with inclusion of ADDLs alone. Moreover, addition of the agents before or after binding of the ADDLs to the cell surface can be compared to identify agents that impact such binding, or that act after binding has occurred.

Example 13

Dose Response Curve for ADDL Cell Binding

15

This example sets forth dose response experiments done to determine whether ADDL binding to the cell surface is saturable. Such saturability would be expected if the ADDLs in fact interact with a particular cell surface receptor.

For these studies, B103 cells were incubated with increasing amounts of ADDLs and ADDL binding was quantitated by FACscan analysis. Results are presented in Fig. 10. These results confirm that a distinct plateau is achieved for ADDL binding. Saturability of ADDL binding occurs at a relative $A\beta$ 1-42 concentration (*i.e.*, ADDL concentration relative to $A\beta$) of about 250 nm.

These results thus confirm that ADDL binding is saturable. Such saturability of ADDL binding, especially when considered with the results of the trypsin studies, validates that the ADDLs are acting through a particular cell surface receptor.

Example 14

Cell-Based ELISA for ADDL Binding Activity

30

This example sets forth a cell-based assay, particularly a cell-based enzyme-linked immunosorbent assay (ELISA) that can be employed to assess ADDL binding activity.

For these studies, 48 hours prior to conduct of the experiment, 2.5×10^4 B103 cells present as a suspension in 100 μL DMEM were placed in each assay well of a 96-well microtiter plate and kept in an incubator at 37°C . 24 hours prior to the conduct of the experiment, ADDLs were prepared according to the method described in Example 1. To begin the assay, each microtiter plate well containing cells was treated with 50 μL of fixative (3.7% formalin in DMEM) for 10 minutes at room temperature. This fixative/DMEM solution was removed and a second treatment with 50 μL formalin (no DMEM) was carried out for 15 minutes at room temperature. The fixative was removed and each well was washed twice with 100 μL phosphate buffered saline (PBS). 200 μL of a blocking agent (1% BSA in PBS) was added to each well and incubated at room temperature for 1 hour. After 2 washes with 100 μL PBS, 50 μL of ADDLs (previously diluted 1:10 in PBS), were added to the appropriate wells, or PBS alone as a control, and the resulting wells were incubated at 37°C for 1 hour. 3 washes with 100 μL PBS were carried out, and 50 μL biotinylated 6E10 (Senetek) diluted 1:1000 in 1% BSA/PBS was added to the appropriate wells. In other wells, PBS was added as a control. After incubation for 1 hour at room temperature on a rotator, the wells were washed 3 times with 50 μL PBS, and 50 μL of the ABC reagent (Elite ABC kit, Vector Labs) was added and incubated for 30 minutes at room temperature on the rotator. After washing 4 times with 50 μL PBS, 50 μL of ABTS substrate solution was added to each well and the plate was incubated in the dark at room temperature. The plate was analyzed for increasing absorption at 405 nm. Only when ADDLs, cells, and 6E10 were present was there a significant signal, as illustrated in Fig. 11.

These results further confirm that a cell-based ELISA assay can be employed as an assay for ADDL-mediated cell binding. In particular, the assay can be carried out by co-incubating or co-administering along with the ADDLs agents that potentially may increase or decrease ADDL formation and/or activity. Results obtained with such co-incubation or co-administration can be compared to results obtained with inclusion of ADDLs alone.

Example 15

Fyn kinase knockout protects against ADDL neurotoxicity

To investigate further the potential involvement of signal transduction in
5 ADDL toxicity, the experiments in this example compared the impact of ADDLs
on brain slices from isogenic *fyn* *-/-* and *fyn* *+/+* animals. Fyn belongs to the Src-
family of protein tyrosine kinases, which are central to multiple cellular signals
and responses (Clark, E.A. & Brugge, J.S. (1995) *Science*, vol. 268, pp. 233-
239). Fyn is of particular interest because it is up-regulated in AD-afflicted
10 neurons (Shirazi *et al.* (1993) *Neuroreport*, vol. 4, pp. 435-437). It also appears
to be activated by conventional A β preparations (Zhang *et al.* (1996) *Neurosci.*
Lett., vol. 211, pp. 187-190) which subsequently have been shown to contain
ADDLs by AFM. Fyn knockout mice, moreover, have reduced apoptosis in the
developing hippocampus (Grant *et al.* (1992) *Science*, vol. 258, pp. 1903-1910).

15 For these studies, Fyn knockout mice (Grant *et al.* (1992) *Science*, vol.
258, pp. 1903-1910) were treated as described in the preceding examples, by
comparing images of brain slices of mice either treated or not treated with ADDLs
for 24 hours to determine dead cells in the DG and CA3 area. The quantitative
comparison (presented in Fig. 12) was obtained with error bars representing
20 means \pm SEM for 4-7 slices.

In contrast to cultures from wild-type animals, cultures from *fyn* *-/-* animals
showed negligible ADDL-evoked cell death, as shown in Fig. 12. For ADDLs, the
level of cell death in *fyn* *+/+* slices was more than five times that in *fyn* *-/-*
cultures. In *fyn* *-/-* cultures, cell death in the presence of ADDLs was at
25 background level. The neuroprotective response was selective; hippocampal cell
death evoked by NMDA receptor agonists (Bruce *et al.* (1995) *Exper. Neurol.*,
vol. 132, pp. 209-219; Vornov *et al.* (1991) *Neurochem.*, vol. 56, pp. 996-1006)
was unaffected (not shown). Analysis (ANOVA) using the Tukey multiple
comparison gave a value of $P < 0.001$ for the ADDL *fyn* *+/+* data compared to all
30 other conditions.

These results confirm that loss of Fyn kinase protected DG and CA3
hippocampal regions from cell death induced by ADDLs. The results validate that
ADDL toxicity is mediated by a mechanism blocked by knockout of Fyn protein
tyrosine kinase. These results further suggest that neuroprotective benefits can

be obtained by treatments that abrogate the activity of Fyn protein tyrosine kinase or the expression of the gene encoding Fyn protein kinase.

Example 16

5

Astrocyte Activation Experiments

To investigate further the potential involvement of signal transduction in ADDL toxicity, the experiments in this example compared the impact on ADDLs on activation of astrocytes.

10

For these experiments, cortical astrocyte cultures were prepared from neonatal (1-2 day old) Sprague-Dawley rat pups by the method of Levison and McCarthy (Levison *et al.* (1991) in *Culturing Nerve Cells* (Banker *et al.*, Eds.), pp. 309-36, MIT Press, Cambridge, MA), as previously described (Hu *et al.* (1996) *J. Biol. Chem.*, vol. 271, pp. 2543-2547). Briefly, cerebral cortex was dissected out, trypsinized, and cells were cultured in α -MEM (Gibco, BRL) containing 10% fetal bovine serum (Hyclone Laboratories Inc., Logan UT) and antibiotics (100 U/mL penicillin, 100 mg/mL streptomycin). After 11 days in culture, cells were trypsinized and replated into 100-mm plates at a density of $\sim 6 \times 10^5$ cells/plate and grown until confluent (Hu *et al.* (1996) *J. Biol. Chem.*, vol. 271, pp. 2543-2547).

15

Astrocytes were treated with ADDLs prepared according to Example 1, or with A β 17-42 (synthesized according to Lambert *et al.* *J. Neurosci. Res.*, vol. 39, pp. 377-384 (1994); also commercially available). Treatment was done by trypsinizing confluent cultures of astrocytes and plating onto 60 mm tissue culture dishes at a density of 1×10^6 cells/dish (e.g., for RNA analysis and ELISAs), into 4-well chamber slides at 5×10^4 cells/well (e.g., for immunohistochemistry), or into 96-well plates at a density of 5×10^4 cells/well (e.g., for NO assays). After 24 hours of incubation, the cells were washed twice with PBS to remove serum, and the cultures incubated in α -MEM containing N2 supplements for an additional 24 hours before addition of A β peptides or control buffer (i.e., buffer containing diluent).

20

25

Examination of astrocyte morphology was done by examining cells under a Nikon TMS inverted microscope equipped with a Javelin SmartCam camera, Sony video monitor and color video printer. Typically, four arbitrarily selected

microscopic fields (20X magnification) were photographed for each experimental condition. Morphological activation was quantified from the photographs with NIH Image by counting the number of activated cells (defined as a cell with one or more processes at least one cell body in length) in the four fields.

5 The mRNA levels in the cultures was determined with use of Northern blots and slot blots. This was done by exposing cells to ADDLs or control buffer for 24 hours. After this time, the cells were washed twice with diethylpyrocarbonate (DEPC)-treated PBS, and total RNA was isolated by RNeasy purification mini-columns (Qiagen, Inc., Chatsworth, CA), as
10 recommended by the manufacturer. Typical yields of RNA were 8 to 30 mg of total RNA per dish. For Northern blot analysis, 5 mg total RNA per sample was separated on an agarose-formaldehyde gel, transferred by capillary action to Hybond-N membrane (Amersham, Arlington Heights IL), and UV crosslinked. For slot blot analysis, 200 ng of total RNA per sample was blotted onto Duralon-
15 UV membrane (Stratagene, La Jolla CA) under vacuum, and UV crosslinked. Confirmation of equivalent RNA loadings was done by ethidium bromide staining or by hybridization and normalization with a GAPDH probe.

 Probes were generated by restriction enzyme digests of plasmids, and subsequent gel purification of the appropriate fragment. Namely, cDNA
20 fragments were prepared by RT-PCR using total RNA from rat cortical astrocytes. RNA was reverse transcribed with a Superscript II system (GIBCO/ BRL), and PCR was performed on a PTC-100 thermal controller (MJ Research Inc, Watertown, MA) using 35 cycles at the following settings: 52°C for 40 seconds; 72°C for 40 seconds; 96°C for 40 seconds. Primer pairs used to amplify a 447 bp
25 fragment of rat IL-1 β were: Forward: 5' GCACCTTCTTTCCCTTCATC 3' [SEQ ID NO:1]. Reverse: 5' TGCTGATGTACCAGTTGGGG 3' [SEQ ID NO:2]. Primer pairs used to amplify a 435 bp fragment of rat GFAP were: Forward: 5' CAGTCCTTGACCTGCGACC 3' [SEQ ID NO:3]. Reverse: 5' GCCTCACATCACATCCTTG 3' [SEQ ID NO:4]. PCR products were cloned into
30 the pCR2.1 vector with the Invitrogen TA cloning kit, and constructs were verified by DNA sequencing. Probes were prepared by *EcoRI* digestion of the vector, followed by gel purification of the appropriate fragments. The plasmids were the rat iNOS cDNA plasmid pAstNOS-4, corresponding to the rat iNOS cDNA bases 3007-3943 (Galea *et al.* (1994) *J. Neurosci. Res.*, vol. 37, pp. 406-414), and the

rat GAPDH cDNA plasmid pTRI-GAPDH (Ambion, Inc., Austin TX).

The probes (25 ng) were labeled with ^{32}P -dCTP by using a Prime-a-Gene Random-Prime labeling kit (Promega, Madison WI) and separated from unincorporated nucleotides by use of push-columns (Stratagene). Hybridization
5 was done under stringent conditions with QuikHyb solution (Stratagene), using the protocol recommended for stringent hybridization. Briefly, prehybridization was conducted at 68°C for about 30 to 60 minutes, and hybridization was at 68°C for about 60 minutes. Blots were then washed under stringent conditions and exposed to either autoradiography or phosphoimaging plate. Autoradiograms
10 were scanned with a BioRad GS-670 laser scanner, and band density was quantified with Molecular Analyst v2.1 (BioRad, Hercules CA) image analysis software. Phosphoimages were captured on a Storm 840 system (Molecular Dynamics, Sunnyvale CA), and band density was quantified with Image Quant v1.1 (Molecular Dynamics) image analysis software.

15 For measurement of NO by nitrite assay, cells were incubated with $A\beta$ peptides or control buffer for 48 hours, and then nitrite levels in the conditioned media were measured by the Griess reaction as previously described (Hu *et al.* (1996) *J. Biol. Chem.*, vol. 271, pp. 2543-2547). When the NOS inhibitor N-nitro-L-arginine methylester (L-name) or the inactive D-name isomer were used, these
20 agents were added to the cultures at the same time as the $A\beta$.

Results of these experiments are presented in Fig. 13. As can be seen in this figure, glia activation increases when astrocytes are incubated with ADDLs, but not when astrocytes are incubated with $A\beta$ 17-42.

These results confirm that ADDLs activate glial cells. It is possible that
25 glial proteins may contribute to neural deficits, for instance, as occur in Alzheimer's Disease, and that some effects of ADDLs may actually be mediated indirectly by activation of glial cells. In particular, glial proteins may facilitate formation of ADDLs, or ADDL-mediated effects that occur downstream of receptor binding. Also, it is known that clusterin is upregulated in the brain of the
30 Alzheimer's diseased subject, and clusterin is made at elevated levels only in glial cells that are activated. Based on this, activation of glial cells by a non-ADDL, non-amyloid stimulus could produce clusterin which in turn might lead to ADDLs, which in turn would damage neurons and cause further activation of glial cells.

Regardless of the mechanism, these results further suggest that neuroprotective benefits can be obtained by treatments that modulate (*i.e.*, increase or decrease) ADDL-mediated glial cell activation. Further, the results suggest that blocking these effects on glial cells, apart from blocking the neuronal effects, may be beneficial.

Example 17

LTP Assay - ADDLs Disrupt LTP

Long-term potentiation (LTP) is a classic paradigm for synaptic plasticity and a model for memory and learning, faculties that are selectively lost in early stage AD. This example sets forth experiments done to examine the effects of ADDLs on LTP, particularly medial perforant path-granule cell LTP.

Injections of intact animals: Mice were anesthetized with urethane and placed in a stereotaxic apparatus. Body temperature was maintained using a heated water jacket pad. The brain surface was exposed through holes in the skull. Bregma and lambda positions for injection into the middle molecular layer of hippocampus are 2 mm posterior to bregma, 1 mm lateral to the midline, and 1.2-1.5 mm ventral to the brain surface. Amyloid β oligomer injections were by nitrogen puff through ~ 10 nm diameter glass pipettes. Volumes of 20-50 nL of amyloid β oligomer solution (180 nM of amyloid β in phosphate buffered saline, PBS) were given over the course of an hour. Control mice received an equivalent volume of PBS alone. The animal was allowed to rest for varying time periods before the LTP stimulus is given (typically 60 minutes).

LTP in injected animals: Experiments follow the paradigm established by Routtenberg and colleagues for LTP in mice (Namgung *et al. Brain Research*, vol. 689, pp. 85-92 (1995)). Perforant path stimulation from the entorhinal cortex was used, with recording from the middle molecular layer and the cell body of the dentate gyrus. A population excitatory postsynaptic potential (pop-EPSP) and a population spike potential (pop-spike) were observed upon electrical stimulation. LTP could be induced in these responses by a stimulus of 3 trains of 400 Hz, 8 x 0.4 ms pulses/train (Namgung *et al. (1995) Brain Res.*, vol. 689, pp. 85-92). Recordings were taken for 2-3 hours after the stimulus (*i.e.*, applied at time 0) to determine if LTP is retained. The animal was then sacrificed immediately, or was

allowed to recover for either 1, 3, or 7 days and then sacrificed as above. The brain was cryoprotected with 30% sucrose, and then sectioned (30 μ M) with a microtome. Some sections were placed on slides subbed with gelatin and others were analyzed using a free-floating protocol. Immunohistochemistry was used to monitor changes in GAP-43, in PKC subtypes, and in protein phosphorylation of tau (PHF-1), paxillin, and focal adhesion kinase. Wave forms were analyzed by machine as described previously (Colley *et al.* (1990) *J. Neurosci.*, vol. 10, pp. 3353-3360). A 2-way ANOVA compares changes in spike amplitude between treated and untreated groups.

10 Fig. 14 illustrates the spike amplitude effect of ADDLs in whole animals. As can be clearly seen in this figure, ADDLs block the persistence phase of LTP induced by high frequency electrical stimuli applied to entorhinal cortex and measured as cell body spike amplitude in middle molecular layer of the dentate gyrus.

15 After the LTP experiment was performed, animals were allowed to recover for various times and then sacrificed using sodium pentobarbital anesthetic and perfusion with 4% paraformaldehyde. For viability studies, times of 3 hours, 24 hours, 3 days, and 7 days were used. The brain was cryoprotected with 30% sucrose and then sectioned (30 μ M) with a microtome. Sections were placed on slides subbed with gelatin and stained initially with cresyl violet. Cell loss was measured by counting cell bodies in the dentate gyrus, CA3, CA1, and entorhinal cortex, and correlated with dose and time of exposure of ADDLs. The results of these experiments confirmed that no cell death occurred as of 24 hours following the LTP experiments.

25 Similarly, the LTP response was examined in hippocampal slices from young adult rats. As can be seen in Fig. 15, incubation of rat hippocampal slices with ADDLs prevents LTP well before any overt signs of cell degeneration. Hippocampal slices (n=6) exposed to 500 nM ADDLs for 45 minutes prior showed no potentiation in the population spike 30 minutes after the tetanic stimulation (mean amplitude 99% \pm 7.6), despite a continuing capacity for action potentials. In contrast, LTP was readily induced in slices incubated with vehicle (n=6), with an amplitude of 138% \pm 8.1 for the last 10 minutes; this value is comparable to that previously demonstrated in this age group (Trommer *et al.* (1995) *Exper. Neurol.*, vol. 131, pp. 83-92). Although LTP was absent in ADDL-treated slices,

their cells were competent to generate action potentials and showed no signs of degeneration.

These results validate that in both whole animals and tissue slices, the addition of ADDLs results in significant disruption of LTP in less than an hour, prior to any cell degeneration or killing. These experiments thus support that ADDLs exert very early effects, and interference with ADDL formation and/or activity thus can be employed to obtain a therapeutic effect prior to advancement of a disease, disorder, or condition (e.g., Alzheimer's disease) to a stage where cell death results. In other words, these results confirm that decreases in memory occur before neurons die. Interference prior to such cell death thus can be employed to reverse the progression, and potentially restore decreases in memory.

Example 18

15 *Early Effects of ADDLs in vivo*

This example sets forth early effects of ADDLs *in vivo* and the manner in knowledge of such early effects can be manipulated.

The primary symptoms of Alzheimer's disease involve learning and memory deficits. However, the link between behavioral deficits and aggregated amyloid deposits has been difficult to establish. In transgenic mice, overexpressing mutant APP under the control of the platelet-derived growth factor promoter results in the deposition of large amounts of amyloid (Games *et al.* (1995) *Nature*, vol. 373, PP. 523-527). By contrast, no behavioral deficits have been reported using this system. Other researchers (*i.e.*, Nalbantoglu, J. *et al.* (1997) *Nature*, vol. 387, pp. 500-505; Holcomb, L. *et al.* (1998) *Nat. Med.*, vol. 4, pp. 97-100) working with transgenic mice report observing significant behavioral and cognitive deficits that occur well before any significant deposits of aggregated amyloid are observed. These behavioral and cognitive defects include failure to long-term potentiate (Nalbantoglu, J. *et al.*, *supra*). These models collectively suggest that non-deposited forms of amyloid are responsible for the early cognitive and behavioral deficits that occur as a result of induced neuronal malfunction. It is consistent with these models that the novel ADDLs described herein are this non-deposited form of amyloid causing the early

cognitive and behavioral defects. In view of this, ADDL modulating compounds according to the invention can be employed in the treatment and/or prevention of these early cognitive and behavioural deficits resulting from ADDL-induced neuronal malfunction, or ADDLs themselves can be applied, for instance, in animal models, to study such induced neuronal malfunction.

Similarly, in elderly humans, cognitive decline and focal memory deficits can occur well before a diagnosis of probable stage I Alzheimer's disease is made (Linn *et al.* (1995) *Arch. Neurol.*, vol. 52, pp. 485-490). These focal memory deficits may result from induced aberrant signaling in neurons, rather than cell death. Other functions, such as higher order writing skills (Snowdon *et al.* (1996) *JAMA*, vol. 275, pp. 528-532) also may be affected by aberrant neuronal function that occurs long before cell death. It is consistent with what is known regarding these defects, and the information regarding ADDLs provided herein, that ADDLs induce these defects in a manner similar to compromised LTP function such as is induced by ADDLs. Along these lines, ADDL modulating compounds according to the invention can be employed in the treatment and/or prevention of these early cognitive decline and focal memory deficits, and impairment of higher order writing skills, resulting from ADDL formation or activity, or ADDLs themselves can be applied, for instance, in animal models, to study such induced defects. In particular, such studies can be conducted such as is known to those skilled in the art, for instance by comparing treated or placebo-treated age-matched subjects.

Example 19

Further Method for Preparing Amyloid β Oligomers (ADDLs)

This Example describes an alternative method for making ADDLs that can be employed instead of, for instance, the methods described in Examples 1 and 4.

Amyloid β monomer stock stock solution is made by dissolving the monomer in hexafluoroisopropanol (HFIP), which is subsequently removed by speed vacuum evaporation. The solid peptide is redissolved in dry DMSO at 5 mM to form a DMSO stock solution, and the ADDLs are prepared by diluting 1 μ l

of the DMSO stock solution into 49 μ l of F12 media (serum-free, phenol-red free). The mixture is vortexed and then incubated at 4°C for 24 hours.

Example 20

5

Further Gel Studies of Amyloid β Oligomers

This Example describes further gel studies done on amyloid β oligomers.

For gel analysis following preparation of the amyloid β oligomers (*i.e.*, oligomers prepared as described in the prior example), 1 μ l of the oligomer solution is added to 4 μ l of F12 and 5 μ l of tris-tricine loading buffer, and then loaded on a pre-made 16.5% tris-tricine gel (Biorad). Electrophoresis is carried out for 2.25 hours at 100 V. Following electrophoresis, the gel is stained using the Silver Xpress kit (Novex). Alternately, instead of staining the gel, the amyloid β species are transferred from the gel to Hybond-ECL (Amersham) in SDS-containing transfer buffer for 1 hour at 100 V at 4°C. The blot is blocked in TBS-T1 containing 5% milk for 1 hour at room temperature. Following washing in TBS-T1, the blot is incubated with primary antibody (26D6, 1:2000,) for 1.5 hours at room temperature. The 26D6 antibody recognizes the amino terminal region of amyloid β . Following further washing, the blot is incubated with secondary antibody (anti-mouse HRP, 1:3500) for 1.5 hours at room temperature. Following more washing, the blot is incubated in West Pico Supersignal reagents (500 μ l of each, supplied by Pierce) and 3 mls of ddH₂O for 5 minutes. Finally, the blot is exposed to film and developed.

Results of such further gel studies are depicted in Fig. 16, which shows a computer-generated image of a densitometer-scanned 16.5% tris-tricine SDS-polyacrylamide gel (Biorad). The figure confirms a range of oligomeric, soluble ADDLs (labeled "ADDLs"), dimer (labeled "Dimer"), and monomer (labeled "Monomer"). This gel system thus enables visualization of distinct ADDLs comprising from at least 3 monomers (trimer) up to about 24 monomers.

What is not depicted in Fig. 16, but which becomes apparent upon comparing gels/Westerns obtained before and after aggregation is the fact that the tetramer band increases upon aggregation, whereas the pentamer through the 24-mer oligomer species appear only after aggregation. The differences

between the silver stained and the immunodetected amounts of the oligomers (especially dimer and tetramer) suggest that the oligomers may represent different conformations obtained upon aggregation.

5

Example 21

Further AFM Studies of Amyloid β Oligomers

This Example describes further AFM studies done on amyloid β oligomers.

AFM was done as described in Example 3 except that fractionation on a
10 Superdex 75 column was not performed, and the field was specifically selected such that larger size globules in the field were measured. The analysis is the same from a technical standpoint as that done in Example 3, but in this instance the field that was specifically selected for and examined allows visualization of oligomers that have larger sizes than those that were measured by the section
15 analysis. AFM was carried out using a NanoScope[®] III MultiMode AFM (MMAFM) workstation using TappingMode[®] (Digital Instruments, Santa Barbara, CA).

The results of these studies are shown in Fig. 17, which is a computer-generated image of an AFM analysis of ADDLs showing various sized structures
20 of different amyloid β oligomers. The adhered structures range in size from 1 to 10.5 nm in z height. Based on this characterization, the structures comprise from 3 to 24 monomeric subunits, consistent with the bands shown on Tris-tricine SDS-PAGE. In separate experiments (not shown) species as high as about 11 nm have been observed.

25

Example 22

Preparation, Characterization and Use of Anti-ADDL Antibodies

Materials & Methods

30

Materials: $A\beta_{1-42}$ was obtained from American Peptide. Cell culture products were obtained from CellGro and Life Technologies. Unless otherwise indicated, chemicals and reagents were from Sigma-Aldrich. The following kits

were used: the Boehringer Mannheim Cell Proliferation (MTT) kit, the Novex Silver Xpress kit, and the Pierce West Femto kit for chemiluminescence. SDS-PAGE gels and buffers were from BioRad. Antibodies 6E10, 6E10Bi, and 4G8 were obtained from Senetek. 26D6 was a gift of Sibia Corporation. Conjugated
5 secondary antibodies were obtained from Jackson Labs and Amersham.

$A\beta$ derived diffusible ligand (ADDL) preparation: $A\beta_{1-42}$ was dissolved in hexafluoro-2-propanol (HFIP) and aliquoted to microcentrifuge tubes. HFIP was removed by lyophilization and the tubes were stored at -20°C . An aliquot of $A\beta_{1-42}$ was dissolved in anhydrous DMSO to make a 5 mM solution. The DMSO
10 solution was then added to cold F12 medium (Life Technologies) to make a 100 μM solution. This solution was incubated at 4°C for at least 24 hours and then centrifuged at 14,000 x g for 10 min. The supernatant is ADDLs, used usually at a 1:10 or 1:20 dilution in medium.

MTT assay: PC12 cells were plated at 30,000 cells/well in 96-well plates
15 and grown overnight. This medium was removed and ADDLs (5 or 10 μM) or vehicle were added in new medium (F12K, 1% horse serum, antibiotic/antimycotic). After 4 hrs at 37°C , MTT (10 μl) was added to each well and allowed to incubate for 4 hours at 37°C . The solubilization buffer (100 μl) was added and the plate was placed at 37°C overnight. The assay was
20 quantified by reading at 550 or 550/690 nm on a plate reader; data were plotted as averages with standard error of the mean (SEM).

Silver stain: The procedure outlined by the manufacturer (Novex) was followed.

Antibody preparation: The polyclonal antibodies were produced and
25 purified by Bethyl Laboratories, Inc., Texas. The initial 24-hour material was sent overnight on ice to the antibody company. It was diluted with complete Freund's adjuvant at 1:1 and injected the day it was received. Antigen labeled +48 hours was thus the material injected. Booster injections continued over several weeks and used incomplete adjuvant. Hyperimmune serum produced in two rabbits was
30 quantified by ELISA against the original antigen solution in a 96-well format. After attainment of an appropriate antibody titer, the animals were bled and antibodies were then collected and purified using an affinity column. The affinity column was prepared by linking an $A\beta_{40}$ solution (50 $\mu\text{g}/\text{ml}$ gel) to agarose via a

cyanogen bromide method. Binding of the appropriate antibodies to the column was monitored by ELISA. The polyclonal antibodies were then removed from the column, fractionated using ammonium sulfate precipitation and ion-exchange chromatography, and sent to us as an IgG preparation of > 95% purity. We received antibodies from two rabbits (M93 and M94) which were each bled a total of three times.

Immunoblotting: Previously published procedures were followed (Zhang, C. *et al.* (1994) *J. Biol. Chem.*, vol. 269, pp. 25247-25250). Briefly, equal amounts of protein or ADDLs were added to sample buffer and loaded on a 16.5% Tris-Tricine gel. For mixed samples, ADDLs were added to protein just before sample buffer and then placed immediately on the gel. The proteins were separated by electrophoresis at 100 v until the sample buffer reached the bottom of the gel. Proteins were then transferred to nitrocellulose at 100 v for 1 hr in the cold. The membrane was blocked for 1 hr at RT with 5% non-fat dry milk in Tris-buffered saline with 0.1% triton. The sample was incubated with primary antibody for 1.5 hr at RT and washed 3 x 15 min. Primary antibody was usually used at a dilution of 1:2000, equivalent to a protein concentration between 0.3 and 0.6 $\mu\text{g/ml}$, depending on the antibody used. The membrane was incubated with secondary antibody for 1 hr at RT (usually a dilution of 1:20,000) and washed the same way. Proteins were visualized with chemiluminescence. Quantification utilized Kodak 1D Image Analysis software for the IS440CF Image Station.

Preparation of rat hippocampal cultures: The procedure of Brewer (Brewer, G.J. (1997) *J. Neurosci.*, vol. 71, pp. 143-155) for preparation of embryonic mouse cultures was followed. The hippocampus was removed from the animal and placed in Hibernate™/B27 medium until all hippocampii were dissected and cleaned. The tissue was then dissociated with papain. Cells were separated by trituration, recombined, and plated on glass coverslips coated with poly-L-lysine (200 $\mu\text{g/ml}$) and laminin (15 $\mu\text{g/ml}$). Plating medium was Neurobasal™-E/B27, supplemented with 0.5mM glutamine, 5ng/ml β -FGF, and antibiotic/antimycotic (Life Technologies). This procedure usually gave us clean, primarily neuronal, cultures and cells that developed long processes. If cultures were not used by three days, the medium was replaced with fresh medium.

ADDL immunofluorescence: Cells were cultured on coated glass coverslips as described previously (Stevens, G.R. *et al.* (1996) *J. Neurosci. Res.*, vol. 46, pp. 445-455). ADDLs were added to cells in serum-free medium for varied times. Free ADDLs were removed by washing with warm medium. Cells
5 were fixed at room temperature in 1.88% formaldehyde for 10 minutes, followed by a post-fix for 15 min. in 3.7% formaldehyde. Bound ADDLs were identified by incubation with M94 polyclonal antibody and visualized using anti-rabbit IgG conjugated to Oregon Green-514 (Jackson Labs). A Nikon Diaphot inverted microscope equipped for epifluorescence was used for analysis.

10

Results

In order to immunize with defined ADDL antigens, we first verified that our preparations consistently provided expected structure and neurotoxicity. ADDL
15 solutions should contain only monomer and toxic oligomers (Lambert, M.P. *et al.* (1998) *Proc. Natl. Acad. Sci. USA*, vol. 95, pp. 6448-6453). To eliminate seeds that promote fibril formation, $A\beta_{1-42}$ from the supplier was first monomerized by dissolving in hexafluoro-isopropanol (HFIP) and then dried for storage (Stine, W.B. *et al.* (2000) *Soc. Neurosci. Abstr.*, vol. 26, p. 800). This monomerized
20 $A\beta_{1-42}$ was used weekly for 8 weeks, reliably giving ADDLs that were at the same concentration ($0.24 \pm .01$ mg $A\beta$ /ml; see Methods). Atomic force microscopy verified that ADDL solutions were fibril-free (not shown), confirming previous observations (Lambert, M.P. *et al.* (1998) *Proc. Natl. Acad. Sci. USA*, vol. 95, pp. 6448-6453). Constituents of each preparation were analyzed further by SDS-
25 PAGE and silver staining and found to consist exclusively of small oligomers and monomers (the predominant constituent, $45 \pm 5\%$). Fig 18A illustrates the composition of a preparation used for immunization. The time points show the status of the initial preparation and the same preparation one day later. There was no change in composition with time. Each preparation also was tested for
30 toxicity to PC12 cells as assayed by impact on MTT reduction. Whether measured immediately after preparation, or one day later, the ADDL solutions showed consistent potency in blocking MTT reduction (Fig. 1B). Impact was essentially maximal by 5 μ M. These results established that immunogens were

consistent throughout the course of the study with respect to protein concentration, oligomer profile, and toxic activity.

ADDL solutions prepared as above (0.23 mg/ml total protein, see Methods) were mixed with 1 ml complete Freund's adjuvant and injected immediately into two rabbits (0.12 mg protein/animal). Booster injections (5) used incomplete adjuvant and continued over 10 weeks. The rabbits were bled three times to obtain ant sera (M93 and M94) which were purified by affinity chromatography and fractionated giving an IgG preparation >95% pure.

The ability of the new antibodies to identify various $A\beta$ species was assessed by immunoblots. Results were compared with those of standard monoclonal antibodies 4G8, 26D6, and 6E10. 26D6 (Kounnas, M.Z., personal communication) and 6E10 (Kim, K.S. *et al.* (1990) *Neurosci. Res. Commun.*, vol. 7, pp. 113-122) recognize similar epitopes of $A\beta$, aa1-12 and 1-16, respectively; 4G8 recognizes aa17-24 of $A\beta$ (Enya, M. *et al.* (1999) *Am. J. Pathol.*, vol. 154, pp. 271-279). Comparisons showed similar efficacies but marked differences in specificity. The three monoclonals recognize monomers as well as oligomeric species. 4G8 also is particularly effective at binding small amounts of dimer. In contrast, the new polyclonal antibodies showed strong preference for oligomeric species. Applied to the same preparation of ADDLs, and in a dose equal to the monoclonals, M94 and M93 recognized only trimer and tetramer (Figs. 19 and 20). Dose response data showed that M93 can bind monomer but only at high concentrations of antibody (Fig. 20). At a dilution at which 6E10 will bind monomer at least as well as oligomers, the M93 antibodies bind only oligomers. Dimer is not recognized by either antibody. These data indicate that the polyclonal antibodies readily recognize higher organized forms of $A\beta$, but not monomer.

Possible non-specific association of antibodies with ADDLs was tested by pre-absorbing antibodies with ADDLs for 2 hours at 4°C. Pre-absorption eliminated all binding in the immunoblot (Fig. 21). To determine if the antibodies might bind non-specifically to neural proteins other than ADDLs, immunoblots were carried out using homogenates from rat brain. The results show little reaction with any proteins in the homogenate (Fig. 22, middle lane). Similar results were obtained with rat postmitochondrial membrane homogenates and

B103 CNS neuroblastoma cell homogenates (not shown). To test if the antibodies can detect ADDLs in the presence of other brain proteins, ADDLs were added to the homogenate before the gel separation and then immunoblotted (Fig. 22, right lane). Trimer and tetramer (filled arrow) were detected, and in addition, the antibodies recognized higher molecular weight species. The most prominent .of these bands are indicated by the open arrow, with trace amounts showing up at higher molecular weights. The higher molecular weight species may be larger oligomers, as previously found in human brain (Guerette, P.A. *et al.* (2000) *Soc. Neurosci. Abstr.*, vol. 25, p. 2129), or perhaps a complex between ADDLs and a second protein such as ApoE (LaDu, M.J. *et al.* (1995) *J. Biol. Chem.*, vol. 270, pp. 9039-9042).

Since the antibodies recognized ADDLs in the presence of other brain proteins, we next tested if they might be useful for microscopy to detect ADDLs bound to cells in culture. Cultures were prepared from E18 rat hippocampus and incubated with ADDLs for 90 min. at 37°C (see Methods). Cells were fixed, incubated with M94, and visualized with a secondary IgG conjugated to Oregon green-514. No signal was seen without ADDLs, consistent with the specificity found in immunoblots. In the presence of ADDLs, M94 detected small puncta localized almost exclusively to neurites (Fig. 23). This punctate binding is similar to that found when ADDLs are visualized with commercially available antibodies (Viola, K.L. *et al.* (2000) *Soc. Neurosci. Abstr.*, vol. 26, p. 1285).

The final experiment was designed to test if the antibodies might target ADDLs in solution and prevent their neurotoxicity. Toxicity was assessed by the impact of ADDLs on MTT reduction in PC12 cells (Shearman, M.S. *et al.* (1994) *Proc. Natl. Acad. Sci. USA*, vol. 91, pp. 1470-1474; Liu, Y. *et al.* (1998) *Proc. Natl. Acad. Sci. USA*, vol. 95, pp. 13266-13271; Liu, Y. & Schubert, D. (1997) *J. Neurochem.*, vol. 69, pp. 2285-2293; Oda, T. *et al.* (1995) *Exp. Neurol.*, vol. 136, pp. 22-31; Lambert, M.P. *et al.* (2000) *Soc. Neurosci. Abstr.*, vol. 26, p. 1285. Control assays of ADDL activity in the presence of pre-immune serum showed a dose-dependent blockade of MTT reduction (Fig. 24, open squares). To test for possible protection, antibodies and ADDLs were incubated together for 2 hours before being assayed. In this case, ADDLs were no longer active (Fig. 24, filled squares). Data shown are for a 4-hour impact of ADDLs. Equivalent results

were obtained in tests of a 24-hour impact (not shown). In addition, protection occurred whether ADDLs were made with the chaperone clusterin or under chaperone-free conditions (not shown). These results demonstrate a potent ability of ADDL antibodies to neutralize neurotoxicity.

5 All of the references cited herein, including patents, patent applications, scientific references, treatises, publications, and the like, are hereby incorporated by reference in their entireties (including references therein) to the extent that they are not contradictory.

10 The foregoing description of the preferred embodiments should not be construed as limiting the invention in any way. One of skill in the art will appreciate that numerous modifications are possible without exceeding the scope of the invention. While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments can be used, and that it is intended that
15 the invention can be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the scope of the invention as defined by the following claims.

CLAIMS

We claim:

1. A composition comprising one or more antibodies that interacts preferentially with soluble, non-fibrillar oligomeric assemblies of amyloid β protein.
5
2. A composition as in claim 1, wherein the assemblies are ADDLs.
3. A composition as in either of claim 1 or claim 2, wherein the one or more antibodies are M90, M93 or M94 antibodies.
10
4. A composition comprising one or more antibodies that bind preferentially to soluble, globular, non-fibrillar protein assemblies of amyloid β_{1-42} .
- 15 5. A composition as in claim 4, wherein the assemblies are ADDLs.
6. A composition as in either of claim 4 or 5, wherein the antibodies are the M90, M93 or M94 antibodies.
- 20 7. A composition comprising antibodies that bind preferentially to amyloid β -derived diffusible ligands (ADDLs).
8. A composition as in claim 7, wherein the antibodies are the M90, M93 or M94 antibodies.
25
9. A composition comprising one or more antibody binding sites that bind preferentially to ADDLs.
10. A composition comprising one or more modified antibody binding sites that bind preferentially to ADDLs.
30
11. A composition consisting of one or more binding sites that preferentially bind to ADDLs.

12. Any composition of claims 1-11, wherein the ADDL binding site is incorporated into a human antibody framework.

5 13. A method for detecting, in fluid taken from a patient, the presence of soluble, non-fibrillar assemblies of amyloid β protein, the method comprising contacting the fluid with the composition as in any one of claims 1-12 and determining the presence of the assemblies.

10 14. A method for detecting, in tissue taken from a patient, the presence of soluble, non-fibrillar assemblies of amyloid β protein, the method comprising homogenizing the tissue, extracting the tissue with a buffer, contacting the buffer with the composition as in any one of claims 1-12 and determining the presence of the assemblies.

15 15. A method for counteracting the effects of soluble, non-fibrillar assemblies of amyloid β protein, the method comprising administering the composition as in any one of claims 1-12 to a patient in need of such treatment.

20 16. A method for detecting the presence of molecules that interfere with the formation of soluble, non-fibrillar assemblies of amyloid β protein, the method comprising contacting any composition of claims 1-12 with a solution of Ab 1-42 incubated in the presence of test molecules under conditions known to form ADDLs, and determining by dot blot or other methods whether ADDLs are
25 present.

17. A method for detecting the presence of molecules that interfere with the binding of soluble, non-fibrillar assemblies of amyloid β protein to specific ADDL receptors on neurons, the method comprising incubation of one or more
30 test compounds with a blot of nerve cell membrane proteins, followed by incubation of the blot with a solution containing ADDLs, followed by washing and contacting the blot with any composition of claims 1-12 to whether the test molecule blocked the binding of ADDLs to the blotted proteins.

18. The method of claim 17 wherein the ADDL receptors have molecular weights of approximately 140 kDa and 260 kDa.




Figure 1




Figure 2




Figure 3




Figure 4.





Figure 5






Figure 7




Figure 8




Figure 9




Figure 10

ADDL Binding ELISA




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24